

CURRICULUM VITAE

Vassilis G Gorgoulis

1. CONTACT DETAILS

Address: Medical School, National Kapodistrian University of Athens, 75 Mikras Asias Str, Goudi, Athens 11527, Greece

Tel/E-mails: (0030) 210-7462352/vgorg@med.uoa.gr, vgorgoulis@gmail.com, vgorg@bioacademy.gr

Site: www.gorgoulis.gr

ORCID ID: 0000-0001-9001-4112

2. CURRENT POSITIONS

1. Professor-Director, Dept. of Histology and Embryology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, (site: www.gorgoulis.gr).
2. Professor and Chair, Clinical and Molecular Pathology, Medical School, University of Dundee, Dundee, UK (elected March 2022).
3. Honorary Professor, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK (site: <http://www.manchester.ac.uk/research/Vasileios.gorgoulis/>).
4. Collaborating Professor, Biomedical Research Foundation, Academy of Athens, Athens, Greece, (site: <http://www.bioacademy.gr/faculty-details/Gsk/vassilis?lang=en>).
5. Member of the board of the Center for New Biotechnologies and Precision Medicine, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
6. Visiting Professor, Faculty of Health and Medical Sciences, University of Surrey, UK.
7. Adjunct Professor, Institute of Biosciences & Applications NCSR "Demokritos", Athens, Greece.

3. EDUCATION - TRAINING

- A. Undergraduate Studies: School of Medicine, University of Athens, Greece (degree: *Summa Cum Laude*) (June 1988)
- B. Post-Graduate Studies:
- i. *PhD thesis*: School of Medicine, University of Athens, Greece (degree: *Summa Cum Laude*) (April 1994)
 - ii. *Medical Specialty*: Pathology (degree: *Summa Cum Laude*) (November 1996)

4. MAJOR SCIENTIFIC ACHIEVEMENTS

A. Our group played a major role in:

I) Establishing the “Oncogene-induced DNA damage model for cancer development” (**Science 2008; Nat Rev Mol Cell Biol 2010; J Pathol 2018**). Based on: **J Pathol 1996; Br J Cancer 1998; Am J Pathol 1998; Cancer 2000; Cancer Res 2001; J Pathol 2002; Am J Pathol 2002; J Pathol 2004; Am J Pathol 2004; Nature 2005; Nature 2006; J Pathol 2006; Int J Cancer 2006; Cancer Res 2007(a); Oncogene 2008; Blood 2008; Am J Pathol 2009; Nature Genetics 2011; Nature Cell Biol 2011; Cancer Res 2012; Cell Death Differ 2014; Cell Mol Life Sci 2014; Cell Rep 2015; Nat Cell Biol 2016; Genomics 2018; Genome Biology 2018; Mol Cell 2021(a); EMBO Rep 2022a** and currently the broader role of DNA damage response pathway in disease development (**Cell 2016** - see also achievement VIII). Achievement I: contributed and led to establishment of Genomic Instability and Senescence as hallmarks of cancer (**Nat Rev Mol Cell Biol 2010; Cancer Disc 2022**). **II**) Clarifying the functional interplay and the timeline of events underlying the two major antitumor checkpoint responses, i.e. DDR and ARF (**Nat Cell Biol 2013; Cell Death Diff 2013; Cell Cycle 2014**). **III**) Revealing the oncogenic role of replication licensing factors Cdc6 and Cdt1 by inducing DNA replication stress and deregulating transcription (**Am J Pathol 2004; Nature 2006; Cancer Res 2007(a), J Cell Biol 2011; Transcription 2012; Semin Cancer Biol 2016; Nat Commun 2016; Nat Cell Biol 2016; PNAS 2016; BMC Genomics 2018; Genome Biology 2018; Mol Cell 2021(a); Mol Cell Oncol 2022**). **IV**) Demonstrating that

Genomic Instability drives Escape from Senescence fueling Cancer Progression (**Cancer Res 2007(a)**; **Nat Cell Biol 2016**; **BMC Genomics 2018**; **Genome Biology 2018**; **Mol Cell 2021(a)**, **J Pathol 2023**). **V**) Developing pioneer senescence biomarkers (two already commercially available under the trademark SenTraGor™ and GLF16) and providing guidelines to detect senescence (**Aging 2013**; **Aging Cell 2017**; **Pharmacol Ther 2018**; **Cell 2019**; **Nat Protoc 2021**; **Mol Cell 2023**; **STAR Prot 2024**). SenTraGor™ is patented through UMIP, University of Manchester and licensed to BioTechne/Tocris and Cayman Chemicals. GLF16 is patented through University of Dundee and recently licensed to QR Laboratories. **VI**) Understanding how cellular senescence is induced and involved in age-related pathologies, including cancer (**EMBO J 2003**; **Lab Invest 2005**; **Nature 2006**; **Am J Pathol 2009**; **Aging 2013**; **Aging Cell 2013**; **Stem Cells 2013**; **Cell Death Differ 2015**; **Mech Ageing Dev 2016**; **Aging Cell 2017**; **J Pathol 2018**; **Int J Mol Sci 2018**; **Pharmacol Ther 2018**; **Nat Commun 2020(a)**; **Nat Commun 2020(b)**; **Cell Rep 2021**; **FEBS J 2021**; **Mol Cell 2021(b)**; **Physiol Rev 2022**; **Europ Res J 2022(a,b)**; **Aging Cell 2023**; **J Pathol 2023**; **Ann Rheum Dis 2024**). **VII**) Exploiting molecular patterns for precision medicine based cancer therapy (**Int J Cancer 2006**; **J Pathol 2006**; **Blood 2008**; **J Cell Mol Med 2010**; **EMBO Rep 2022b**; **J Exp Clin Cancer Res. 2023**; **Mol Cancer 2024**). **VIII**) Contributing to our understanding of the role that inflammation plays in cancer development (**EMBO J 2003**; **Cancer Res 2007(b)**; **Cancer Cell 2013**; **Cancer Cell 2014**; **Pharmacol Ther 2015**; **Cell Death Diff 2015**; **Cell Rep 2016**; **Cell 2016**; **Cell Death Diff 2017**; **Hepatology 2017**; **Nat Comm 2018**: see **Appendix I** in the last page; **Nat Commun 2020 (b)**). **IX**) Development of machine learning algorithms to predict biological responses (**Pharmacol Ther 2019**; **Cell Reports 2019**; **Cancer Res 2020**; **Cell Rep Meth 2023**; **Machine learning: a tool to shape the future of medicine. In: Handbook of Machine Learning Applications for Genomics. Studies in big data (series), Springer-Verlag 2021**; **Nat Comput Sci 2024**). **X**) Providing evolutionary evidence that modern humans dispersed into Europe and Asia (150 thousand years) earlier than initially thought [**Nature 2019**: featured (77th) among the 100 top most influential studies of 2019 (<https://www.altmetric.com/top100/2019/>; **Sci Adv 2022**)].

B. i. EMBO member (elected May 2015) (<http://www.embo.org/news/press-releases/2015/embo-announces-new-members-for-2015>)

ii. European Academy of Cancer Sciences (EACS) member (elected May 2022) (<https://www.europeancanceracademy.eu/>)

iii. Academia Europaea (AE) member (elected May 2022) (https://www.ae-info.org/ae/Member/Gorgoulis_Vassilis)

iv. Among the most Highly Cited Greek Scientists internationally:

https://www.adscientificindex.com/citation-ranking/?country_code=gr&q=Gorgoulis

v. Coordinator of the Greek national: “Emblematic action to handle SARS-CoV-2 infection: Epidemiological study in Greece via extensive testing for viral and antibody detection, sequencing of the virome and genetic analysis of the carriers” (2020-2022)

vi. Appointed by the government: national reference lab for COVID-19 testing.

5. PUBLICATIONS – CITATIONS - COMMUNICATIONS

- **354** publications in international peer reviewed journals (<http://www.ncbi.nlm.nih.gov/pubmed/?term=Gorgoulis>)

- **27** publications (**Am J Pathol 2004**, **Nature 2005**, **Nature 2006**, a.o.) are featured as “All time article recommendations” on the F1000 Faculty Prime site.

- **1** publication (**Nature 2019**) featured (77th) among the 100 top most influential studies of 2019 (<https://www.altmetric.com/top100/2019/>;

<https://www.altmetric.com/top100/2019/?subject=Studies+in+Human+Society&details=69411337>)

- Sept 2021 recognition: among the top 0,1% experts in cellular senescence

(https://twitter.com/Daily_Experts/status/1436228969683095556?ref_src=twsrc%5Etfw)

- **>46230** citations

- **14** chapters in international text-books

- **>150** communications at conferences, seminars, symposia, etc (including **30 Keynote/Distinguished lectures** (eg **EMBO** presentations: 2007, 2011, 2013, 2015, 2017; **Oxford University Seminars 2010**; **Cold Spring Harbor Lab 2013**; **EACR 2014**; **Weizmann Institute**

Seminars 2015; ICSA 2018, 2019; Umeå Univ 2022: Distinguished Guest Seminars; Buck Institute for Aging Research in Novato, California, USA 2023: SenoTherapeutics Summit; FORTH 2024).

- **h index: 86**

6. REVIEWER

- In more than **65** international peer reviewed journals (eg Cell, Nature, Nat Rev Cancer, Nat Cell Biol, Cancer Cell, Mol Cell, Genome Biol, Nat Comm, EMBO J, J Cell Biol, J Clin Invest, Curr Opin Cell Biol, Trends Genetics, Current Biology, Ann Human Genet, Cell Death Diff, Cancer Res, Current Biology, Cell Reports, Sem Cancer Biol, Oncogene, Cell Death Dis, J Pathol, Clin Cancer Res, FEBS Lett, J Cell Mol Med, Plos One, Carcinogenesis, Cancer Lett, J Mol Med, Mut Res, Mech Aging Dev, Lung Cancer, BMC Mol Biol, Biochimie, Cell Oncol, Mol Can Ther, Exp Cell Res, BMC Cancer, J Clin Immun, BMC Gastroenterology, Histology-Histopathology, Cytokine, Can Invest, J Biomolecular Techniques, Scandinavian Journal of Rheumatology, Anti-Cancer Drugs, Oral Oncology, European Journal of Oral Sciences, IUBMB Life, Otolaryngology-Head and Neck Surgery, Molecular Biology Reports, The International Journal of Biochemistry & Cell Biology, Cellular&Molecular Biology Letters, Arch Biochem Biophys, Cancer Chemotherapy and Pharmacology, Molecular Oncology, Biotechnic and Histochemistry, Recent patents on DNA & Gene sequences)

- For grant awards

- a. International:** **1)** European Research Council (ERC): i. Advanced Grants-ERC LS1-Panel member 2020 and 2022 (Molecular Biology, Biochemistry, Structural Biology and Molecular Biophysics), ii. External reviewer for Synergy/Advanced/Starting; **2)** EMBO Young Investigator Programme, **3)** Cancer Research UK; **4)** Medical Research Council, UK; **5)** Leukemia Research, UK; **6)** Israel Science Foundation; **7)** Deutsches Krebsforschungszentrum (DKFZ), Germany; **8)** Netherlands, NWO, Innovational Research Incentives Scheme Veni 2013 ALW; **9)** Agence Nationale De La Recherche (French National Research Agency), France; **10)** French National Cancer Institute (INCa); **11)** Biotechnology and Biological Sciences Research Council (BBSRC) UK; **12)** Dutch Cancer Society, Holland; **13)** Ministry of Science and Technology, Israel; **14)** "Tumour escape" from canceropole CLARA (Cancéropôle Lyon Auvergne Rhône-Alpes); **15)** The Neye Foundation, Denmark; **16)** Austrian Science Fund; **17)** European Hematology Association, Netherlands; **18)** Swiss Cancer League, Switzerland; **19)** Swiss National Science Foundation; **20)** Portuguese Science and Technology Foundation; **21)** Academy of Sciences of the Czech Republic; **22)** Czech Science Foundation; **23)** HRB eGrant Ver2.0, Health Research Awards 2011; **24)** BIRAX Ageing; **25)** Barts Charity; **26)** U.S. FOOD & DRUG ADMINISTRATION, Chief Scientist Grants Program, USA, **27)** FONDECYT-CHILE, **28)** Fondazione AIRC per la Ricerca sul Cancro Ets, **29)** Executive Agency for Higher Education Research Development and Innovation Funding (UEFISCDI) of the Romanian National Research Council (CNCS).
- b. Domestic:** **1)** Greek Ministry of Education; **2)** General Secretariat for Research and Technology (GSRT); **3)** Karatheodori, University of Patras, Greece; **4)** IKY, **5)** ELIDEK, **6)** EPAN EK

- Member of review panel for the evaluation of international institutes

1) Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany (2018)

2) Center for Chromosome Stability (CCS), Danish National Research Foundation, Copenhagen, Denmark (2019)

7. TEACHING AND SUPERVISING RESPONSABILITIES

- a. Undergraduate teaching:** School of Medicine: Histology - Cell Biology, Embryology and Cancer Biology (emphasis on upper and lower respiratory system), Anthropology; Dentistry School: Histology – Cell Biology, Embryology

- b. *Postgraduate Supervising*: i) Supervisor or member of the supervising committee for >20 PhD students over the last 5 years; ii) Supervisor of >10 students for MSc or MPhil diploma thesis over the last 5 years
- c. Post Doctoral Supervising: Supervisor of 10 PostDocs over the last 5 years

8. COLLABORATIONS

- a. Institute of Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, Copenhagen, Denmark. **Prof J Bartek**
- b. Dept of Molecular Biology, University of Geneva, Geneva, Switzerland. **Prof TD Halazonetis**
- c. Dept of Molecular Cell Biology, The Weizmann Institute of Science. Rehovot, Israel. **Profs M Oren**
- d. University of Dundee, Dundee, UK. **Profs R Petty and JJ Blow**
- e. Dept of Human Molecular Genetics and Biochemistry, Sackler Medical School, Tel Aviv University, Tel Aviv, Israel. **Prof Y Shiloh**
- f. Institute of Pathology, University Medical Centre Göttingen, Göttingen, Germany. **Prof A Papantonis**
- g. Telomeres and cellular senescence program, c/o IFOM-IEO, Milan, Italy. Head of Lab & Group: **Dr F d'Adda di Fagagna**
- h. Lab of Human Carcinogenesis, NCI-CCR, National Institutes of Health, Bethesda, Maryland. **Prof C Harris**
- i. Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark. **Prof CS Sørensen**
- j. Tumor Suppression Group, Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. **Prof M Serrano**
- k. Dept of Molecular Medicine and Biotechnology, Medical School of Rijeka, Rijeka, Croatia. **Prof S Volarevic**
- l. Signalling and Cell Cycle Laboratory, Oncology Research Programmes, Institute for Research in Biomedicine (IRB), Barcelona, Spain. **Prof A Nebreda**
- m. Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden. **Prof T Helleday**
- n. Laboratory of Cellular Senescence and Age-related Pathologies, European Research Institute for the Biology of Aging (ERIBA), University Medical Center Groningen (UMCG), Netherlands. **Dr M Demaria**
- o. National Heart and Lung Institute, Imperial College London, London, UK, **Prof P Barnes**
- p. Computing Sciences Department, Bocconi University, Milan Italy. **Prof F Buffa**
- q. Institute of Molecular Biology & Biotechnology, FORTH, Greece. **Assoc Prof P Verginis**

9. MEMBERSHIP IN SCIENTIFIC ASSOCIATIONS

1. EMBO member
2. European Academy of Cancer Sciences (EACS)
3. Academia Europaea (AE)
4. European Association for Cancer Research
5. International Cell Senescence Association (ICSA)
6. European Society of Pathology
7. Hellenic Society of Pathology
8. International Union Against Cancer (UICC)
9. Hellenic Association for Molecular Cancer Research
10. Hellenic Society for Biochemistry and Molecular Biology
11. American Mathematical Society (AMS)
12. Hellenic Mathematical Society (HMS)

10. Journals - Editorial board membership

- npj Aging – Nature, Editorial Board Member (<https://www.nature.com/npjamd/editors>) - 2024
- Review and Associate Editor for Cancer Cell Biology (specialty section of Frontiers in Cell and Developmental Biology) 2022 (<https://www.frontiersin.org/journals/cell-and-developmental-biology/sections/cancer-cell-biology#editorial-board>)
- F1000 Research 'Cellular senescence in stress and aging' Collection Advisor Inquiry 2022 (<https://f1000research.com/collections/cell-sene-stres-agin/about-this-collection>)
- Experimental Gerontology (<https://www.sciencedirect.com/journal/experimental-gerontology/about/editorial-board>)
- International Journal of Molecular Sciences (<http://www.mdpi.com/journal/ijms/sectioneditors/biochemistry>)
- In vivo (<http://iiar-anticancer.org/220-2/>)
- Mechanisms of Ageing and Development (<https://www.journals.elsevier.com/mechanisms-of-ageing-and-development/editorial-board/vassilis-gorgoulis-md-phd>)

11. GRANTS AWARDED

Domestic: 20 grants with approx. total budget >8.500.000 euros

Representative: **i)** Applied Research for Precision Medicine under “Hellenic Precision Medicine Network” (HPMN), 2023-2025; **ii)** Emblematic actions: Handling SARS-CoV-2 infection: Epidemiological study in Greece via extensive testing for viral and antibody detection, sequencing of the virome and genetic analysis of the carriers (GSRT No 2020ΣE01300001), 2020-2022; Application of artificial intelligence for the development of drugs and new therapies (GSRT No 2020ΣM01300002), 2020-2022; **iii)** *HFRJ*: CEMA, 2021-2024; Hippo, 2019-2021; PACOREL, 2020-2023; **iv)** *GSRT*: Emblematic action in collaboration with Intelligencia 2020; EIIAvEK, 2020; EIIAvEK, 2018; “ARISTEIA II” program, 2014-2015; "Post-doctoral Reinforcement" 2012-2015; "ENTER", 2006-2007; “Pythagoras” 2004-2005; "PENED 2003", 2004; Framework Program Research and Technology (FPRT) II, Activity 1.2, 1998 - 2001; YIIEP97, 1998 - 2001; **v)** *IKY Foundation*: IKY-Siemens Excellence programs, 2015-2017; **vi)** *EPEAEK, Greek Ministry of Education*: "Heraklitos II", 2010-2013; "Pythagoras II", 2005-2006; "Heraklitos", 2005; **vii)** *Greek National Board of Health*, 1996.

European Community: 6 grants with approx. total budget >7.500.000 euros

Specific: **1)** COST 2023-2025 (OC-2023-1-26592 SENESCENCE2030); **2)** ERC Advanced (FIRSTSTEPS) 2022-2025; **3)** Horizon 2020, ITN (SYNTRAIN), 2016-2020; **4)** FP7, REGPOT (INsPiRE), 2011-2014; **5)** FP7, (INFLA-CARE), 2008-2010; **6)** FP7, (GENICA), 2008-2010; **7)** FP5, (SACROHN), 2000-2002; **8)** FP4, CRAFT, 1997-2000.

International and Private funding bodies: 18 grants with approx. total budget >2.500.000 euros

Specific: **1)** Sonia & Nikos Kotopoulos Trust/Medi Jeunesse, New Jersey, USA donation, **2)** Lab Supplies donation, **3)** MRC iCASE Leadership, University of Manchester, UK, **4)** Haris Pappas donation, **5)** PathLAKE for Data to Early Diagnosis and Precision Medicine strand of the Industrial Strategy Challenge Fund, managed and delivered by UK Research and Innovation (UKRI), **6)** Small Business Research Initiative (SBRI) Healthcare Challenge on Cancer - NHS UK, **7)** NIHR i4i-connect: DeepMed-University of Manchester, UK, **8)** KIKPE Greece, **9)** “Thomas Helleday Foundation” Sweden, **10)** AstraZeneca Hellas; **11)** BIC Hellas; **12)** DHI Hellas; **13)** ELPEN; **14)** Hollister Hellas S.A.; **15)** Novartis Hellas S.A.; **16)** Roche Hellas S.A.; **17)** GENESIS Pharma S.A.; **18)** Pfizer Hellas S.A.; **19)** Wyeth Hellas S.A.; **20)** Marousis AE (Covidien).

12. CLINICAL SERVICES

Pathology and molecular diagnostic services:

- SARS-CoV-2 detection and genome sequencing
- Pathology services for various biopsy materials
- Molecular diagnostics services:
 - i) detection of pathogens: HPV, EBV, HSV, Mycobacterium, etc
 - ii) K-Ras, B-Raf mutation detection

- European regional scheme organizer of the European Society of Pathology in the annually K-Ras European Quality Assurance Program, related to the anti-EGFR therapy (URL: <http://kras.eqascheme.org/>).
- Accredited with excellence by the European Society of Pathology for K-Ras mutation detection

13. FELLOWSHIPS, RECOGNITIONS and PRIZES AWARDED

- **May 2022:** election as member of the Academia Europaea
- **May 2022:** election as member of the European Academy of Cancer Sciences
- **Nov 2021:** Best oral presentation for the study “RASSF1A disrupts the NOTCH signaling axis via SNURF/RNF4-mediated ubiquitination of HES1” awarded at the 71st Panhellenic Congress of the Greek Society of Biochemistry and Molecular Biology, Athens, Greece.
- **Sept 2021:** among the **top 0,1% experts in cellular senescence** (https://twitter.com/Daily_Experts/status/1436228969683095556?ref_src=twsrc%5Etfw)
- **Oct 2019:** Recognition on the contribution towards basic research in the field of head & neck cancer from the Hellenic Head & Neck Cancer Society, Hotel Crowne Plaza, Athens, Greece.
- **May 2018:** Best poster announcement for the study “**The E3, E4 ubiquitin ligase UBE4B in human cancer**” awarded at the **10th Panhellenic congress of the Hellenic Society of Basic and Clinical Pharmacology**, Ioannina, Greece.
- **September 2016:** EMBO poster prize for the study "Chronic p53-independent p21 expression shifts from excision repair to DNA double-strand break repair promoting chromosomal instability", in the **EMBO Workshop "Nuclear function and cell fate choice"**, Kyllini, Greece.
- **October 2015:** Heidelberg, EMBL, awarded EMBO membership upon election
- **December 2014:** **Mousoulou L. family Award** for the study "Functional interplay between the DNA-damage response kinase ATM and ARF tumor suppressor protein in human cancer" was awarded to Prof. Vassileios G. Gorgoulis by the **Academy of Athens**
- **May 2010:** Award “**Prof. N.X. Papacharalampous**” for the study “The overexpression of the licensing factor CDC6 downregulates E-Cadherin expression” in the **12th Hellenic Congress of Pathology**
- **May 2008:** Award “**Prof. N.X. Papacharalampous**” for the study “The role of p53 in the deregulated expression of E2F1 in osteosarcomas” in the **11th Hellenic Congress of Pathology**
- **November 2007:** **Praise** for the best poster for the study “The role of iNOS inhibition with the elective inhibitor 1400W in experimental aortic aneurysm of rats” was awarded in the **8th Greek-Cypriot Congress of Surgery**
- **May 2007:** The study “Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions” that was published in Nature 2005; 434(7035): 907-913” was awarded by the **Rector Council of the National and Kapodistrian University of Athens as one of the best studies conducted** by a member of the University and published in greek or international journals during the academic period 2005-2006
- **January 2007:** **2007 Award of Excellence from the Association of Professors from the Medical School**, National Kapodistrian University of Athens (EKIPA)
- **May 2006:** **Praise** for the study “Evaluation of claspin as proliferation marker in normal and cancerous human tissues” in the **10th Hellenic Congress of Pathology**
- **May 2006:** **Praise** for the study “Expression of the transcriptional factor E2F1 in the chronic liver disease and the hepatocellular carcinoma” in the **10th Hellenic Congress of Pathology**
- **May 2006:** Award “**Prof. N.X. Papacharalampous**” for the study “Presence of centrosomal abnormalities in Non-Small Cell Lung Carcinomas and its relation with ploidy and overexpression of Cyclin E” in the **10th Hellenic Congress of Pathology**
- **January 2006:** The study “Overexpression of the replication licensing regulators hCdt1 and hCdc6 characterizes a subset of non-small-cell lung carcinomas. Synergistic effect

with mutant p53 on tumor growth and chromosomal instability – evidence of E2F1 transcriptional control over hCdt1” , was awarded by the **Rector Council of the National and Kapodistrian University of Athens as one of the best studies conducted** by a member of the University and published in greek or international journals during the academic period 2003-2004

- **November 2004: Prize for the 2nd best poster** for the study “p53-Dependent Icam-1 Over-Expression In Senescent Human Cells. Their Identification In Atherosclerotic Lesions” was awarded in the **4th European Congress of Biogerontology**, Newcastle upon Tyne, UK
- **November 2004: Prize for the 2nd best oral presentation** for the study “Correlation among polymorphisms in the TOLL-4 receptor, CD14 and CARD15/NOD2 and inflammatory bowel disease” was awarded in the **24th Hellenic Congress of Gastroenterology**
- **October 2004: “Papanicolaou Cytopathology Research Award”** for the study “Overexpression of the replication licensing regulators hCdt1 and hCdc6 characterizes a subset of non-small cell lung carcinomas. Synergistic effect with mutant p53 on tumor growth and chromosomal instability. Evidence of E2F-1 transcriptional control over hCdt1” was awarded in the **30th European Congress of Cytology**
- **March - July 2004: Scholarship by UICC** for the research project: “Investigation of the E2F-1 induced p73-dependent apoptosis in colon cancer after DNA damage” that was funded with 3509\$
- **May 2004:** The study “Transcription factor E2F-1 acts as a growth promoting factor and is associated with adverse prognosis non-small cell lung carcinomas” that was published in J Pathol 2002; 198:142-156 was awarded by the **Rector Council of the National and Kapodistrian University of Athens as one of the best studies conducted** by a member of the University and published in greek or international journals during the academic period 2002-2003
- **January 2004: Praise for the best research study** “Elective inhibition of the inducible NO synthase (iNOS) in aorta aneurysm” in the **9th Hellenic Congress of Vascular Surgery – Angiology**
- **October 2003:** Patent diploma was awarded for the “Molecular method for the typing of Mycobacterium avium subsp. Paratuberculosis” by the **Organization of Industrial Property**
- **June 2003:** The study “The mutation Leu1007fsinsC in the NOD2 gene predisposes for the inflammatory phenotype of Chron’s disease in the greek population” was awarded the **prize for the best novel study** in the **2nd Hellenic Congress of Inflammatory Bowel Diseases**
- **January 2003:** The study “Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small cell lung carcinomas. Relationship with p53 and MDM2 protein expression” that was published in Am J Pathol 1998; 153” , was awarded by the **Rector Council of the National and Kapodistrian University of Athens as one of the best studies conducted** by a member of the University and published in greek or international journals during the academic period 1998-1999
- **November 2002: Award “K. Tarlatzi”** for the study “International interlaboratory study for the development of a molecular method for the typing of Mycobacterium avium spp Paratuberculosis in fresh and fixed biologic material from cattle, sheep and birds” in the **9th Hellenic Veterinary Congress**
- **May 2002:** The study “Overexpression of the p27KIP1 protein in advanced invasive breast cancer” was awarded from the **Athens Medical Society** in the 28th Hellenic Medical Congress
- **April 2002: “Galinos” award** for the study “The complement inhibitor CD59(MIRL) and the adhesive molecule CD58(LFA-3), two new gene targets in the genomic region of p53” was awarded by the **Hellenic Society of General Pathology** in the 8th Hellenic Congress of Pathology

- **May 2001: First Prize** for the study “Prognostic significance of p53-Her2/neu and Cathepsin D in invasive breast cancer” in the **7th Hellenic Congress of Surgical Oncology**
- **March 2001: Third Prize** for the study “Apoptosis and Proliferation of epithelial cells in H. Pylori (HP) gastritis. Correlation with the histological parameters and alterations after eradication” in the **6th Hellenic Congress of GSCHP, 2001**
- **April 2000: “Galinos” award** for the study “Deregulated expression of the oncogene c-mos in Non-Small Cell Lung Cancer. Relation with the oncosuppressive protein p53, genomic instability and tumour kinetic parameters” was awarded by the **Hellenic Society of General Pathology** in the 7th Hellenic Congress of Pathology
- **January 2000:** The study “Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene” that was published in Br J Cancer 1998; 77: 374-384, was awarded by the **Rector Council of the National and Kapodistrian University of Athens as one of the best studies conducted** by a member of the University and published in greek or international journals during the academic period 1997-98
- **December 1999: The “L. Mousoulou” family award** from the Academy of Athens for the study “Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression”
- **May 1999: Second Prize for the “Sotiris Papastamatis” award** for the study “oral presentation from young investigator for the study: “Applications of a novel molecular method for the identification and typing of mycobacteria in archival paraffin embedded material with granulomatous inflammation” was awarded from the **Athens Medical Society** in the 25st Hellenic Medical Congress
- **December 1997: First Prize for best study** of the congress for the study: “Diagnostic evaluation of tuberculosis and sarcoidosis cases with a novel molecular technique on archive material embedded in paraffin” was awarded from the **Hellenic Society of Pulmonary Medicine** in the 9th Greek Congress of Pulmonary diseases
- **November 1997: Award** for the study “Loss of Heterozygosity in the chromosomal region 9p21 in breast cancer is related with deregulated expression of the oncosuppressive protein p16” from the **Scientific Committee of the “Agios Savvas” Athens Oncology Hospital** in the 9th Hellenic Oncology Congress
- **March 1996: Third Prize** for best study of the congress for the study: “Immunohistochemical and Molecular evaluation of the mdm2 gene product in Bronchogenic Carcinoma. Relationship to p53 protein immunohistochemical status and clinicopathological features” was awarded from the **Hellenic Society of Pulmonary Medicine** in the 8th Greek Congress of Pulmonary diseases
- **March 1996: First Prize** for best study of the congress for the study: “The role of the expression of Matrix Metalloproteases and their inhibitors in the determination of invasive/metastatic potential of Squamous bronchogenic carcinomas” was awarded from the **Hellenic Society of Pulmonary Medicine** in the 8th Greek Congress of Pulmonary diseases
- **May 1995: First Prize for oral presentation** from young investigator for the study: “Expression of p53 and mutation of its gene in dysplastic lesions and Squamous carcinomas of the larynx in relation to the presence of HPV and the proliferation marker PCNA. Correlation of the findings with the clinicopathological parameters was awarded from the **Athens Medical Society** in the 21st Hellenic Medical Congress
- **May 1994: First Prize for oral presentation** from young investigator for the study: “PCR applications in the diagnosis of tuberculosis from paraffin embedded tissues” was awarded from the **Athens Medical Society** in the 20th Hellenic Medical Congress
- **April 1994:** The study “The expression of the Epidermal Growth Factor receptor (EGFR) and of the oncoprotein c-erbB-2 in the carcinomas of the transitional cell epithelium (TCC) of the bladder. Immunohistochemical analysis and molecular analysis with differential PCR” was awarded the **“Katsara” prize** for the best study encompassing novel techniques from the **Hellenic Society of General Pathology**

- **September 1993: First Award** for the study: “Allelic imbalance in Chromosome 17 (17p13.1) and mutations in p53 oncosuppressive gene, in gastrointestinal tract malignancies” awarded by the **Hellenic Society of Gastroenterology**

14. ORGANIZER OF INTERNATIONAL CONFERENCES/ MEETINGS/ WORKSHOPS (key organizer)

- a. 2nd Genomic Instability Workshop, GENICA FP7 Health Programme, Athens, May 2009
- b. 1st International Conference on Molecular Cancer Research, Royal Olympic Hotel, Athens, November 2009
- c. EMBO Workshop, Chromosome Structure, Damage & Repair, September, Cape Sounio Hotel, 2011
- d. International workshop on: “Ageing and Cancer Cell Biology: Convergent and divergent molecular mechanisms”, Athens July, 2013
- e. International workshop on: “Oncogenic Pathways and Antitumor Responses”, Athens April, 2014
- f. Senescence in neural development and neurodegeneration, symposium of the 7th Mediterranean Neuroscience Conference, Marrakech, June 23-27, 2019
- g. International Cell Senescence Association (ICSA) conference, Athens, 9-12 Sept 2019

15. INTERNATIONAL INVITATIONS (at workshops, seminars, conferences)

1. **Invited lecture** at the 34th Annual Meeting of the European Society for Radiation Biology (ESRB) and the Annual Scientific Meeting of the Association for Radiation Research (ARR), Leicester, UK, September 2005
2. **EMBO Workshop** “Molecular mechanisms of cell cycle control in normal and malignant cells”, Spetses island, Greece, October 2007
3. **Invited seminar** at IFOM-IEO, Milan, October 2008
4. **Invited seminar** at Gray Institute for Radiation Oncology & Biology 2010 Seminar Series, Oxford University, November 2010
5. **EMBO Workshop** “Chromosome Structure, Damage & Repair”, Cape Sounio, Greece, September 2011
6. **Invited lecture** at the TransMedRi project, University of Rijeka Faculty of Medicine, Rijeka, Croatia, May 2013
7. **Invited lecture** at International Workshop “Ageing and cancer cell biology: Convergent and divergent molecular mechanisms”, Athens, July 2013
8. **Chairman and speaker at the Cold Spring Harbor Laboratory meeting Special Session** “Eukaryotic DNA Replication & Genome Maintenance”, Cold Spring Harbor Laboratory, USA, September 2013
9. **Invited seminar** at University of Geneva, December 13th, 2013
10. **International workshop** on “Ageing and cancer cell biology: Convergent and divergent molecular mechanisms”, Athens, July 2013
11. **EMBO Conference** “The DNA damage response in cell physiology and disease”, Cape Sounio, Greece, October 2013
12. **Invited seminar** at BRIC, Copenhagen BioCenter, March 27th, 2014
13. 23rd Biennial Congress of the **European Association for Cancer Research (EACR)** “From Basic Research to Personalised Cancer Treatment”, Munich, Germany, July 2014
14. **Invited seminar** at Tel Aviv University, May 18th, 2015
15. **Invited seminar** at Hebrew University, Givat Ram, Jerusalem, May 20th, 2015
16. **Invited seminar** at Hebrew University, Ein Kerem, Jerusalem, May 21st, 2015
17. **Invited seminar** at Weizmann Institute, May 25th, 2015
18. **Invited seminar** at Uppsala University, Nov 4th, 2015
19. **Invited seminar** at Karolinska Institutet, Stockholm, Nov 5th, 2015
20. **EMBO Conference** “The DNA damage response in cell physiology and disease”, Cape Sounio, Greece, Oct 2017

21. **Invited seminar** at IRB, Barcelona, 26 Oct, 2017
22. **IUBMB Meeting** “Molecular aspects of aging& longevity”, Athens, Greece, 16-19 Nov 2017
23. **ESTRO 37 symposium** on ‘Radiation induced senescence’, Barcelona, Spain, 20-24 Apr 2018
24. "**4th Mancunian Skin Club (MSC) Annual International Workshop**", Manchester, UK, 10-11 May, 2018.
25. **International Cell Senescence Association (ICSA)** conference, Montreal, Canada, 8-11 July 2018
26. **6th International Multithematic Bio-Medical Congress (IMBMC)**, Nicosia, Cyprus, Nov 14-18 2018
27. Invitation talk at the **Distinguished Guest Seminar Series** of the **Umeå Centre for Microbial Research (UCR)**, Umeå University, Sweden, May 2022
28. Invited speaker at **MICSE event (Minimal Information on Cellular Senescence Experimentation): “Senescence in vivo”**, Wiggers-Bernard Conference, Vienna 14th of June, 2023.
29. Invited *keynote speaker* at the **SenoTherapeutics Summit 2023**, Buck Institute for Aging Research in Novato, California, USA, November 7 – 8, 2023.
30. Invited *keynote speaker* at the **Mini Symposium “Current challenges in cancer research: from bench to bedside.”** Institute of Molecular Biology & Biotechnology, FORTH, Crete, March 29, 2024.
31. Invited speaker at the 74th “*National Conference*” of the Hellenic Society of Biochemistry & Molecular Biology, Thessaloniki, Dec 13-15, 2024.
32. Invited speaker at the *annual British Society for Rheumatology* conference, Manchester, Apr 28-30, 2025.
33. Invited speaker at the Forum “**Senotherapeutics Revolution: Transforming Aging and Cancer Therapy**” IBSA Foundation, Lugano, Switzerland, 29 June - 1 July 2025.
34. Invited speaker at the 49th FEBS Congress, session “**Cell stress, cell senescence and cell death decisions**”, Constantinople, July 5-9, 2025.

16. PATENTS

- October 2003: WIPO Publication No: WO/2005/035787 MOLECULAR DETECTION OF MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS, IPC: C12Q 1/68: Patent diploma was awarded for the “Molecular method for the typing of Mycobacterium avium subsp. Paratuberculosis” by the Organization of Industrial Property
- June 2021 and March 2022: EPO Publication No: EP3475265B1 and EP3475287B1, respectively, regarding SBB analogues chemical synthesis, method(s) and application(s) for senescence detection*
- Patent pending: UK Patent Application Number GB1803531.1, regarding “Novel lipofuscin quantification detection”
- Patent pending: Greece Application No OBI 2410-0004635983, UK Patent Application No P350806GR, International Application No PCT/GB2024/050047 for “Hydrophilic compounds”**

Note: * the SBB analogue compound SenTraGor is commercially available from Cayman, Biotechnie and Lab Supplies, and has been recommended for senescence detection (**Cell 2019** and **Nat Protoc 2021**).

** the GLF16 compound is commercially available from QR Laboratories (<https://glf16.gr/>) and has been recommended for senescence detection (**Cell 2024**).

17. OTHER DISTINCTIONS / ACCREDITATIONS / RESPONSABILITIES

- Associate Guest Editor in the: Bioessays – 2021
- Lead Guest Editor in the: Cells – 2020
- Lead Guest Editor in the: Cells – 2019

- Lead Guest Editor in the: Mechanisms of Ageing and Development – 2019
- Lead Guest Editor in the: Frontiers Cell and Developmental Biology – 2019
- Lead Guest Editor in the: Frontiers Cellular Neuroscience – 2019
- Associate Guest Editor in the: Seminars in Cancer Biology – 2017
- Lead Guest Editor in the: International Journal of Molecular Sciences - 2015
- Lead Guest Editor in the: Journal of Biomedicine and Biotechnology - 2012
- Among the most Highly Cited Greek Scientists: <http://www.highlycitedgreekscientists.org/>
- Member of the TES Committee, which is responsible for quality assessment of all Greek Research Institutes
- Member of the National Ethics Committee (Ethniki Epitropi Deontologias)
- Member of the National Stem Cell Committee
- Member of the steering board of the New Biotechnologies and Personalized Medicine Center of the Medical School, National Kapodistrian University of Athens
- Member of various committees for directorship elections in Greek Research Institutes
- Referee for international Institutes (eg University of Liverpool, UK; Columbia University, NY, USA)
- Recognition of our work as a historical milestone in cell cycle and cancer research (Lavin MF, **Nature Reviews Molecular Cell Biology** 2008; Malumbres & Barbacid, **Nature Reviews Cancer**, 2009; Dobbeltstein M & Sorensen CS, **Nature Reviews Drug Discovery**, 2015)

18. BOOK CHAPTERS

1. Lagopati N, Efstathopoulos E P, Veroutis D, Katifelis H, Theocharous G, Pantelis P, Evangelou K, **Gorgoulis V G**, Gazouli M. *Hybrid Multifunctional Nanomaterials for Diagnostic and Therapeutic Applications*. In: Pharmaceutical Nanobiotechnology for Targeted Therapy. Springer International Publishing, 489-519, 2022.
2. Hazapis O, Lagopati N, Pezoulas VC, Papayiannis GI, Fotiadis DI, Skaltsas D, Vergetis V, Tsirigos A, Stratis IG, Yannacopoulos AN, **Gorgoulis VG**. *Machine learning: a tool to shape the future of medicine*. In: Handbook of Machine Learning Applications for Genomics. Studies in big data (series) V: 103, Springer-Verlag 2021.
3. Evangelou K, **Gorgoulis VG**. *Senescence*. In: Encyclopedia of Molecular Pharmacology. Springer-Nature 2022.
4. Georgakopoulou E, Evangelou K, **Gorgoulis VG**. *Premalignant Lesions and Cellular Senescence*. In: Cellular Senescence in Disease. Elsevier 2021.[#]
- [#] **2023 PROSE Award** (<https://publishers.org/news/association-of-american-publishers-announces-finalists-and-category-winners-for-2023-prose-awards/>)
5. Pateras IS, Theodorou DP, Chouliari NV, Veroutis D, Passias PG, Evangelou K, **Gorgoulis VG**. *In situ detection of miRNAs in senescent cells in archival material*. In: Senolytics in Disease, Ageing and Longevity. Healthy Ageing and Longevity series, Springer Nature 2020.
6. Vasileiou PVS, Magiorkinis G, Lagiou P, **Gorgoulis V**. *Analytic methods for systems medicine*. In: Translational systems medicine and oral disease. Academic Press, Elsevier 2019.
7. Iliadou E, Pateras I, Evangelou K, **Gorgoulis V** and Kyrodimos E. *The DNA Damage Response Pathway and Autophagy During Human Laryngeal Carcinogenesis*. In: Head and Neck Cancer, Chapter 5, www.avidscience.com, 2018.
8. Kotzamanis G, Kotsinas A, Papalois A, **Gorgoulis VG**. *Targeting the Lung: Challenges in Gene Therapy for Cystic Fibrosis*. In: Gene Therapy - Tools and Potential Applications, Chapter 22, InTech, open science 2013

9. Kotzamanis G, Abdulrazzak H, Kotsinas A, **Gorgoulis VG**. *Non-Viral Gene Therapy Vectors Carrying Genomic Constructs*. In: Non-Viral Gene Therapy, Chapter 1, InTech, open science 2011
10. Zachariades M, Evangelou K, Kastrinakis NG, Papanagnou P, **Gorgoulis VG**. *Molecular Carcinogenesis*. In: Key topics in surgical research and methodology, Springer 1st ed, Chapter 74, pages 975 – 1004
11. Kotsinas A, Lontos M, Pateras I, **Gorgoulis VG**. *Molecular techniques in Surgical Research*. In: Key topics in surgical research and methodology, Springer 1st ed, Chapter 73, pages 951-974
12. Evangelou K., Tsantoulis PK, Kotsinas A, **Gorgoulis VG**. *The opposing roles of E2Fs in cancer*. In: Control of cellular physiology by transcription factors E2F, Research Signpost, Chapter 13, pages 223 – 241
13. Lontos M, Evangelou K, Koutsami M, **Gorgoulis V**. *The c-mos proto-oncogene, a meiotic gene in cancer development*. In: Genes, Genomes and Genomics, Regency Publications (2007) Volume 2, Chapter 2, pages 16-33
14. **Gorgoulis VG**, Zacharatos P, Kotsinas A. *Role of immunohistochemical expression of beta-catenin in lung carcinoma*. In: Handbook of Immunohistochemistry and in situ Hybridization of Human Carcinomas: Molecular Genetics; Lung and Breast Carcinomas. Academic Press 2004

19. PUBLICATIONS

(<http://www.ncbi.nlm.nih.gov/pubmed/?term=Gorgoulis>)

1. Magkouta S, Veroutis D, Papaspyropoulos A, Georgiou M, Lougiakis N, Pippa N, Havaki S, Palaiologou A, Thanos DF, Kambas K, Lagopati N, Boukos N, Pouli N, Marakos P, Kotsinas A, Thanos D, Evangelou K, Sampaziotis F, Tamvakopoulos C, Pispas S, Petty R, Kotopoulos N, **Gorgoulis V**. *Generation of a selective senolytic platform using a micelle-encapsulated Sudan Black B conjugated analog*. **Nat Aging**. 2024 Dec 27. Online ahead of print. **IF: 17.0**
2. Magkouta S, Markaki E, Evangelou K, Petty R, Verginis P, **Gorgoulis V**. *Decoding T cell senescence in cancer: is revisiting required?* **Semin Cancer Biol**. 2024 Nov 29;108:33-47. **IF: 12.1**
3. Ntintas OA, Daglis T, **Gorgoulis VG**. *Harnessing deep learning to build optimized ligands*. **Nat Comput Sci**. 2024 Nov;4(11):809-810. **IF: 12.0**
4. Gkekas I, Katsamakas S, Mylonas S, Fotopoulou T, Magoulas GE, Tenchiu AC, Dimitriou M, Axenopoulos A, Rossopoulou N, Kostova S, Wanker EE, Katsila T, Papahatjis D, **Gorgoulis VG**, Koufaki M, Karakasiliotis I, Calogeropoulou T, Daras P, Petrakis S. *AI Promoted Virtual Screening, Structure-Based Hit Optimization, and Synthesis of Novel COVID-19 S-RBD Domain Inhibitors*. **J Chem Inf Model**. 2024 Nov 25;64(22):8562-8585. **IF: 5.7**
5. Triantafyllopoulou E, Perinelli DR, Forys A, Pantelis P, **Gorgoulis VG**, Lagopati N, Trzebicka B, Bonacucina G, Valsami G, Pippa N, Pispas S. *Unveiling the Performance of Co-Assembled Hybrid Nanocarriers: Moving towards the Formation of a Multifunctional Lipid/Random Copolymer Nanoplatform*. **Pharmaceutics**. 2024 Sep 13;16(9):1204. **IF: 4.9**
6. Vasileiadis A, Bozidis P, Konstantinidis K, Kesesidis N, Potamiti L, Kolliopoulou A, Beloukas A, Panayiotidis MI, Havaki S, **Gorgoulis VG**, Gartzonika K, Karakasiliotis I. *A Novel Dhillonvirus Phage against Escherichia coli Bearing a Unique Gene of Intergeneric Origin*. **Curr Issues Mol Biol**. 2024 Aug 23;46(9):9312-9329. **IF: 2.8**
7. Ogrodnik M, Carlos Acosta J, Adams PD, d'Adda di Fagagna F, Baker DJ, Bishop CL, Chandra T, Collado M, Gil J, **Gorgoulis V**, Gruber F, Hara E, Jansen-Dürr P, Jurk D, Khosla S, Kirkland JL, Krizhanovsky V, Minamino T, Niedernhofer LJ, Passos JF, Ring NAR, Redl H, Robbins PD, Rodier F, Scharffetter-Kochanek K, Sedivy JM, Sikora E, Witwer K, von Zglinicki T, Yun MH, Grillari J, Demaria M. *Guidelines for minimal information on cellular senescence experimentation in vivo*. **Cell**. 2024 Aug 8;187(16):4150-4175. doi: 10.1016/j.cell.2024.05.059. **IF: 45.5**
8. Angelopoulou A, Theocharous G, Valakos D, Polyzou A, Magkouta S, Myriantopoulos V, Havaki S, Fiorillo M, Tremi I, Vachlas K, Nisotakis T, Thanos DF, Pantazaki A, Kletsas D, Bartek J, Petty R, Thanos D, McCrimmon RJ, Papaspyropoulos A, **Gorgoulis VG**. *Loss of the tumour suppressor LKB1/STK11 uncovers a leptin-mediated sensitivity mechanism to mitochondrial uncouplers for targeted cancer therapy*. **Mol Cancer**. 2024 Jul 25;23(1):147. doi: 10.1186/s12943-024-02061-4. **IF: 27.7**
9. Ridgway H, Moore GJ, Gadanec LK, Zulli A, Apostolopoulos V, Hoffmann W, Węgrzyn K, Vassilaki N, Mpekoulis G, Zouridakis M, Giastas P, Vidali VP, Kelaidonis K, Matsoukas MT, Dimitriou M, Mavromoustakos T, Tsiodras S, **Gorgoulis VG**, Karakasiliotis I, Chasapis CT, Matsoukas JM. *Novel benzimidazole*

- angiotensin receptor blockers with anti-SARS-CoV-2 activity equipotent to that of nirmatrelvir: computational and enzymatic studies. Expert Opin Ther Targets. 2024 May; 28(5):437-459. doi: 10.1080/14728222.2024.2362675. IF: 5.8*
10. **Gorgoulis VG**, Evangelou K, Klionsky DJ. *The DNA damage response and autophagy during cancer development: an antagonistic pleiotropy entanglement. Autophagy. 2024 Jun 10:1-3. doi: 10.1080/15548627.2024.2362121. Online ahead of print. IF: 13.3*
 11. Kalisperati P, Spanou E, Pateras IS, Evangelou K, Thymara I, Korkolopoulou P, Kotsinas A, Vlachoyiannopoulos PG, Tzioufas AG, Kanellopoulos C, **Gorgoulis VG**, Sougioultzis S. *Helicobacter pylori Eradication Reverses DNA Damage Response Pathway but Not Senescence in Human Gastric Epithelium. Int J Mol Sci. 2024 Mar 31;25(7):3888. IF: 5.6*
 12. Pantelis P, Theocharous G, Veroutis D, Vagena IA, Polyzou A, Thanos DF, Kyrodimos E, Kotsinas A, Evangelou K, Lagopati N*, **Gorgoulis VG***, Kotopoulos N. *Pulsed Electromagnetic Fields (PEMFs) Trigger Cell Death and Senescence in Cancer Cells. Int J Mol Sci. 2024 Feb 20;25(5):2473. (*co-correspondence) IF: 5.6*
 13. Vagena IA, Gatou MA, Theocharous G, Pantelis P, Gazouli M, Pippa N, **Gorgoulis VG**, Pavlatou EA, Lagopati N. *Nanoparticle-Mediated Radiotherapy: Functionalized ZnO-Based Nanocomposites for Diverse Biological Applications: Current Trends and Future Perspectives. Nanomaterials (Basel). 2024 Feb 21;14(5):397. IF: 5.3*
 14. Magkouta S, Veroutis D, Pousias A, Papaspyropoulos A, Giannetti K, Pippa N, Lougiakis N, Kambas K, Lagopati N, Polyzou A, Georgiou M, Chountoules M, Pispas S, Foutadakis S, Kyrodimos E, Pouli N, Marakos P, Kotsinas A, Verginis P, Valakos D, Vatsellas G, Petty R, Thanos D, Demaria M, Evangelou K, Di Micco R, **Gorgoulis VG**. *One-step rapid tracking and isolation of senescent cells in cellular systems, tissues, or animal models via GLF16. STAR Protoc. 2024 Mar 7;5(1):102929. IF:-*
 15. Kouri MA, Spyratou E, Kalkou ME, Patatoukas G, Angelopoulou E, Tremi I, Havaki S, **Gorgoulis VG**, Kouloulis V, Platoni K, Efstathopoulos EP. *Nanoparticle-Mediated Radiotherapy: Unraveling Dose Enhancement and Apoptotic Responses in Cancer and Normal Cell Lines. Biomolecules. 2023 Nov 29;13(12):1720. IF: 5.5*
 16. Veroutis D, Argyropoulou OD, Goules AV, Kambas K, Moore GJ, Palamidis DA, Evangelou K, Havaki S, Polyzou A, Valakos D, Xingi E, Karatza E, Boki KA, Cavazza A, Kittas C, Thanos D, Ricordi C, Marvisi C, Muratore F, Galli E, Croci S, Salvarani C*, **Gorgoulis VG***, Tzioufas AG*. *Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways. BMJ Ann Rheum Dis 2023 Nov 24: ard-2023-224467. (*co-correspondance) IF: 27.4*
 17. Ridgway H, Orbell JD, Matsoukas MT, Kelaidonis K, Moore GJ, Tsiodras S, **Gorgoulis VG**, Chasapis CT, Apostolopoulos V, Matsoukas JM. *W254 in furin functions as a molecular gate promoting anti-viral drug binding: Elucidation of putative drug tunneling and docking by non-equilibrium molecular dynamics. Comput Struct Biotechnol J. 2023 Sep 9;21:4589-4612. IF: 6.155*
 18. Magkouta S, Veroutis D, Pousias A, Papaspyropoulos A, Pippa N, Lougiakis N, Kambas K, Lagopati N, Polyzou A, Georgiou M, Chountoules M, Pispas S, Foutadakis S, Pouli N, Marakos P, Kotsinas A, Verginis P, Valakos D, Mizi A,

- Papantonis A, Vatsellas G, Galanos P, Bartek J, Petty R, Serrano M, Thanos D, Roussos C, Demaria M, Evangelou K, **Gorgoulis VG**. *A fluorophore-conjugated reagent enabling rapid detection, isolation and live tracking of senescent cells*. **Mol Cell**. Oct 5;83(19):3558-3573.e7. **IF: 19.328**
19. Vlachogiannis NI, Evangelou K, Ntari L, Nikolaou C, Denis MC, Karagianni N, Veroutis D, **Gorgoulis V**, Kollias G, Sfikakis PP. *Targeting senescence and inflammation in chronic destructive TNF-driven joint pathology*. **Mech Ageing Dev**. 2023 Aug 7;214:111856. **IF: 5.498**
 20. Evangelou K, Belogiannis K, Papaspyropoulos A, Petty R, **Gorgoulis VG**. *Escape from senescence: molecular basis and therapeutic ramifications*. **J Pathol**. 2023 Aug 7. **IF: 9.883**
 21. Papaspyropoulos A, Hazapis O, Altulea A, Polyzou A, Verginis P, Evangelou K, Fouteri M, Papantonis A, Demaria M, **Gorgoulis V**. *Decoding of translation-regulating entities reveals heterogeneous translation deficiency patterns in cellular senescence*. **Ageing Cell**. 2023 Aug 7:e13893. **IF: 11.005**
 22. Fragkou PC, Ikonomidis I, Benas D, Kavatha D, Moschopoulos CD, Protopapas K, Kostelli G, Thymis J, Mpirmpa D, Galani I, Tsakona M, Oikonomopoulou C, Theocharous G, **Gorgoulis VG**, Gallos P, Tsiodras S, Antoniadou A, Papadopoulos A, Triantafyllidi H. *Endothelial Glycocalyx Integrity in Treatment-Naïve People Living with HIV before and One Year after Antiretroviral Treatment Initiation*. **Viruses**. 2023 Jul 5;15(7):1505. **IF: 5.818**
 23. Mourkioti I, Polyzou A, Veroutis D, Theocharous G, Lagopati N, Gentile E, Stravokefalou V, Thanos DF, Havaki S, Kletsas D, Panaretakis T, Logothetis CJ, Stellas D, Petty R, Blandino G, Papaspyropoulos A, **Gorgoulis VG**. *A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer*. **J Exp Clin Cancer Res**. 2023 Jul 29;42(1):187. **IF: 11.3**
 24. Theocharous G, Papaspyropoulos A, **Gorgoulis V**. *The survival of curaxins in the cancer arena*. **Bioessays**. 2023 Sep;45(9):e2300112. **IF: 4.653**
 25. Vlachogiannis NI, Ntouros PA, Pappa M, Kravvariti E, Kostaki EG, Fragoulis GE, Papanikolaou C, Mavroeidi D, Bournia V-K, Panopoulos S, Laskari K, Arida A, **Gorgoulis VG**, Tektonidou MG, Paraskevis D, Sfikakis PP, Souliotis VL. *Chronological Age and DNA Damage Accumulation in Blood Mononuclear Cells: A Linear Association in Healthy Humans after 50 Years of Age*. **Int. J. Mol. Sci**. 2023, 24(8): 7148. **IF: 6.208**
 26. Badwan BA, Liaropoulos G, Kyrodimos E, Skaltsas D, Tsirigos A, **Gorgoulis VG**. *Machine learning approaches to predict drug efficacy and toxicity in oncology*. **Cell Rep Methods**. 2023 Feb 21;3(2):100413. **IF: 9.995**
 27. Papadopoulou-Fermeli N, Lagopati N, Pippa N, Sakellis E, Boukos N, **Gorgoulis VG**, Gazouli M, Pavlatou EA. *Composite Nanoarchitectonics of Photoactivated Titania-Based Materials with Anticancer Properties*. **Pharmaceutics**. 2022 Dec 30;15(1):135. **IF: 6.525**
 28. Pantelis P, Theocharous G, Lagopati N, Veroutis D, Thanos DF, Lampoglou GP, Pippa N, Gatou MA, Tremi I, Papaspyropoulos A, Kyrodimos E, Pavlatou EA, Gazouli M, Evangelou K, **Gorgoulis VG**. *The Dual Role of Oxidative-Stress-Induced Autophagy in Cellular Senescence: Comprehension and Therapeutic Approaches*. **Antioxidants** (Basel). 2023 Jan 11;12(1):169. **IF: 7.675**

29. Manoussakis MN, Svolaki IP, Hazapis O, Zerva L, **Gorgoulis VG**, Magiorkinis G. *Postgenomic Bioinformatic Analysis of Nucleic Acid Sequences Expressed in the Salivary Gland Epithelial Cells of Primary Sjögren's Syndrome Patients in Search of Microorganisms and Endogenous Retroviruses*. **Mediterr J Rheumatol**. 2022 Sep 30;33(3):371-374. **IF: 1.140**
30. Brevini T, Maes M, Webb GJ, John BV, Fuchs CD, Buescher G, Wang L, Griffiths C, Brown ML, Scott WE 3rd, Pereyra-Gerber P, Gelson WTH, Brown S, Dillon S, Muraro D, Sharp J, Neary M, Box H, Tatham L, Stewart J, Curley P, Pertinez H, Forrest S, Mlcochova P, Varankar SS, Darvish-Damavandi M, Mulcahy VL, Kuc RE, Williams TL, Heslop JA, Rossetti D, Tysoe OC, Galanakis V, Vila-Gonzalez M, Crozier TWM, Bargehr J, Sinha S, Upponi SS, Fear C, Swift L, Saeb-Parsy K, Davies SE, Wester A, Hagström H, Melum E, Clements D, Humphreys P, Herriott J, Kijak E, Cox H, Bramwell C, Valentijn A, Illingworth CJR; UK-PBC research consortium, Dahman B, Bastaich DR, Ferreira RD, Marjot T, Barnes E, Moon AM, Barritt AS 4th, Gupta RK, Baker S, Davenport AP, Corbett G, **Gorgoulis VG**, Buczacki SJA, Lee JH, Matheson NJ, Trauner M, Fisher AJ, Gibbs P, Butler AJ, Watson CJE, Mellis GF, Dougan G, Owen A, Lohse AW, Vallier L, Sampaziotis F. *FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2*. **Nature**. 2023 Mar;615(7950):134-142. **IF: 69.504**
31. Tremi I, Havaki S, Georgitsopoulou S, Terzoudi G, Lykakis IN, Iliakis G, Georgakilas V, **Gorgoulis VG**, Georgakilas AG. *Biological Response of Human Cancer Cells to Ionizing Radiation in Combination with Gold Nanoparticles*. **Cancers** (Basel). 2022 Oct 17;14(20):5086. **IF: 6.575**
32. Balzeau A, Albessard-Ball L, Kubicka AM, Filippo A, Beudet A, Santos E, Bienvenu T, Arsuaga JL, Bartsiokas A, Berger L, Bermúdez de Castro JM, Brunet M, Carlson KJ, Daura J, **Gorgoulis VG**, Grine FE, Harvati K, Hawks J, Herries A, Hublin JJ, Hui J, Ives R, Joordens JA, Kaifu Y, Kouloukoussa M, Léger B, Lordkipanidze D, Margvelashvili A, Martin J, Martínón-Torres M, May H, Mounier A, du Plessis A, Rae T, Röding C, Sanz M, Semal P, Stratford D, Stringer C, Tawane M, Temming H, Tsoukala E, Zilhão J, Zipfel B, Buck LT. *Frontal sinuses and human evolution*. **Sci Adv**. 2022 Oct 21;8(42):eabp9767. **IF: 14.957**
33. Petropoulos M, Champeris Tsaniras S, Nikou S, Maxouri S, Dionellis VS, Kalogeropoulou A, Karamichali A, Ioannidis K, Danalatos IR, Obst M, Naumann R, Delinasios GJ, **Gorgoulis VG**, Roukos V, Anastassiadis K, Halazonetis TD, Bravou V, Lygerou Z, Taraviras S. *Cdt1 overexpression drives colorectal carcinogenesis through origin overlicensing and DNA damage*. **J Pathol**. 2023 Oct 9. doi: 10.1002/path.6017. **IF: 9.883**
34. Evangelou K, Vasileiou PV, Papaspyropoulos A, Hazapis O, Petty R, Demaria M, **Gorgoulis VG**. *Cellular senescence and cardiovascular diseases: moving to the "heart" of the problem*. **Physiol Rev**. 2023 Jan 1;103(1):609-647. doi: 10.1152/physrev.00007.2022. **IF: 46.500**
35. Mourkioti I, Angelopoulou A, Belogiannis K, Lagopati N, Potamianos S, Kyrodimos E, **Gorgoulis V**, Papaspyropoulos A. *Interplay of Developmental Hippo-Notch Signaling Pathways with the DNA Damage Response in Prostate Cancer*. **Cells**. 2022 Aug 7;11(15):2449. **IF: 7.666**
36. Detsika MG, Nikitopoulou I, Veroutis D, Vassiliou AG, Jahaj E, Tsipilis S, Athanassiou N, Gakiopoulou H, **Gorgoulis VG**, Dimopoulou I, Orfanos SE, Kotanidou A. *Increase of HO-1 Expression in Critically Ill COVID-19 Patients Is Associated with Poor Prognosis and Outcome*. **Antioxidants** (Basel). 2022 Jun 29;11(7):1300. **IF: 7.675**

37. Mavrogonatou E, Angelopoulou M, Rizou SV, Pratsinis H, **Gorgoulis VG**, Kletsas D. *Activation of the JNKs/ATM-p53 axis is indispensable for the cytoprotection of dermal fibroblasts exposed to UVB radiation.* **Cell Death Dis.** 2022 Jul 25;13(7):647. **IF: 9.685**
38. Tsaridou S, Velimezi G, Willenbrock F, Chatzifrangkeskou M, Elsayed W, Panagopoulos A, Karamitros D, **Gorgoulis V**, Lygerou Z, Roukos V, O'Neill E, Pefani DE. *53BP1-mediated recruitment of RASSF1A to ribosomal DNA breaks promotes local ATM signaling.* **EMBO Rep.** 2022 Jun 27:e54483. doi: 10.15252/embr.202154483. **IF: 9.071**
39. Katsouda A, Valakos D, Dionellis VS, Bibli SI, Akoumianakis I, Karaliota S, Zuhra K, Fleming I, Nagahara N, Havaki S, **Gorgoulis VG**, Thanos D, Antoniadis C, Szabo C, Papapetropoulos A. *MPST sulfurtransferase maintains mitochondrial protein import and cellular bioenergetics to attenuate obesity.* **J Exp Med.** 2022 Jul 4;219(7):e20211894. **IF: 17.579**
40. Anastasiou IA, Eleftheriadou I, Tentolouris A, Sarantis P, Angelopoulou A, Katsaouni A, Mourouzis I, Karamouzis MV, **Gorgoulis V**, Pantos C, Tentolouris N. *Low concentrations of bisphenol A promote the activation of the mitochondrial apoptotic pathway on Beta-TC-6 cells via the generation of intracellular reactive oxygen species and mitochondrial superoxide.* **J Biochem Mol Toxicol.** 2022 May 20:e23099. **IF: 3.568**
41. Havaki S, Evangelou K, Paschalaki K, Petty R, Barnes PJ, **Gorgoulis VG**. *Identification of coronavirus particles by electron microscopy: a complementary tool for deciphering COVID-19.* **Eur Respir J.** 2022b Apr 29:2200754. **IF: 33.795**
42. Ridgway H, Moore GJ, Mavromoustakos T, Tsiodras S, Ligielli I, Kelaidonis K, Chasapis CT, Kate Gadanec L, Zulli A, Apostolopoulos V, Petty R, Karakasiliotis I, **Gorgoulis VG***, Matsoukas JM*. *Discovery of a new generation of angiotensin receptor blocking drugs: receptor mechanisms and in silico binding to enzymes relevant to covid-19.* **Comput Struct Biotechnol J.** 2022; 20:2091-2111. (*co-correspondance) **IF: 6.155**
43. Palmero I, **Gorgoulis V**, Varela-Nieto I. Editorial: *The Role of Cellular Senescence in Health and Disease.* **Front Cell Neurosci.** 2022 Mar 30;16:882417. **IF: 6.147**
44. Nikitaki Z, Velalopoulou A, Zanni V, Tremi I, Havaki S, Kokkoris M, **Gorgoulis VG**, Koumenis C, Georgakilas AG. *Key biological mechanisms involved in high-LET radiation therapies with a focus on DNA damage and repair.* **Expert Rev Mol Med.** 2022 Mar 31;24:e15. **IF: 7.615**
45. Konstantinidou AE, Angelidou S, Havaki S, Papanizou K, Spanakis N, Chatzakis C, Sotiriadis A, Theodora M, Donoudis C, Daponte A, Skaltsounis P, **Gorgoulis V**, Papaevangelou V, Kalantaridou S, Tsakris A. *Stillbirth due to SARS-CoV-2 placentitis without evidence of intrauterine transmission to fetus: association with maternal risk factors.* **Ultrasound Obstet Gynecol.** 2022 Mar 30. **IF: 8.678**
46. Vasileiou PVS, Siasos G, **Gorgoulis VG**. *Molecular biomarkers in cardio-oncology: Where we stand and where we are heading.* **Bioessays.** 2022 Mar 30:e2100234. **IF: 4.653**
47. Angelopoulou A, Papaspyropoulos A, Papantonis A, **Gorgoulis VG**. *CRISPR-Cas9-mediated induction of large chromosomal inversions in human bronchial epithelial cells.* **STAR Protoc.** 2022 Mar 18;3(2):101257. **IF: -**
48. Zampetidis CP, Papantonis A, **Gorgoulis VG**. *Escape from senescence: revisiting cancer therapeutic strategies.* **Mol Cell Oncol.** 2022 Feb 15;9(1):2030158. **IF: 1.420**
49. Evangelou K, Veroutis D, Paschalaki K, Foukas P, Lagopati N, Dimitriou M, Papaspyropoulos A, Bindu K, Hazapis O, Polyzou A, Havaki S, Kotsinas A, Kittas C,

- Tzioufas A, de Leval L, Vassilakos D, Tsiodras S, Stripp B, Papantonis A, Blandino G, Karakasiliotis I, Barnes P, **Gorgoulis V**. *Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis*. **Eur Respir J** 2022a Feb 3:2102951. **IF: 33.795**
50. Vlachoyiannopoulos PG, Chatzis LG, Goules AV, Argyropoulou OD, Englezopoulou A, Stergiou I, Voulgarelis M, Tsanakas P, Exarchos T, **Gorgoulis VG**, Fotiadis DI, Tzioufas AG. *Patient-centered approaches for patients with systemic autoimmune rheumatic diseases: development and evolution*. **Expert Rev Clin Immunol**. 2022 Jan 21:1-9. **IF: 5.124**
51. Paschalaki K, Rossios C, Pericleous C, MacLeod M, Rothery S, Donaldson GC, Wedzicha JA, **Gorgoulis V**, Randi AM, Barnes PJ. *Inhaled corticosteroids reduce senescence in endothelial progenitor cells from patients with COPD*. **Thorax**. 2022 Jan 13:thoraxjnl-2020-216807. **IF: 9.102**
52. Papaspyropoulos A, Angelopoulou A, Mourkioti I, Polyzou A, Pankova D, Toskas K, Lanfredini S, Pantazaki AA, Lagopati N, Kotsinas A, Evangelou K, Chronopoulos E, O'Neill E, **Gorgoulis V**. *RASSF1A disrupts the NOTCH signaling axis via SNURF/RNF4-mediated ubiquitination of HES1*. **EMBO Rep**. 2022 Feb 3;23(2):e51287. **IF: 9.071**
53. Zampetidis CP, Galanos P, Angelopoulou A, Zhu Y, Polyzou A, Karamitros T, Kotsinas A, Lagopati N, Mourkioti I, Mirzazadeh R, Polyzos A, Garnerone S, Mizi A, Gusmao EG, Sofiadis K, Gál Z, Larsen DH, Pefani DE, Demaria M, Tsirigos A, Crosetto N, Maya-Mendoza A, Papaspyropoulos A, Evangelou K, Bartek J, Papantonis A, **Gorgoulis VG**. *A recurrent chromosomal inversion suffices for driving escape from oncogene-induced senescence via subTAD reorganization*. **Mol Cell**. 2021a Dec 2;81(23):4907-4923.e8. **IF: 19.328**
54. Papaspyropoulos A, Hazapis O, Lagopati N, Polyzou A, Papanastasiou AD, Lontos M, **Gorgoulis VG**, Kotsinas A. *The Role of Circular RNAs in DNA Damage Response and Repair*. **Cancers** (Basel). 2021 Oct 26;13(21):5352. **IF: 6.575**
55. Karakasiliotis I, Lagopati N, Evangelou K, **Gorgoulis VG**. *Cellular senescence as a source of SARS-CoV-2 quasispecies*. **FEBS J**. 2021 Oct 15. doi: 10.1111/febs.16230. Online ahead of print. **IF: 5.622**
56. Kitsou K, Kotanidou A, Paraskevis D, Karamitros T, Katzourakis A, Tedder R, Hurst T, Sapounas S, Kotsinas A, **Gorgoulis V**, Spoulou V, Tsiodras S, Lagiou P, Magiorkinis G. *Upregulation of Human Endogenous Retroviruses in Bronchoalveolar Lavage Fluid of COVID-19 Patients*. **Microbiol Spectr**. 2021 Oct 6:e0126021. **IF: 9.043**
57. Kaklamanos A, Belogiannis K, Skendros P, **Gorgoulis VG**, Vlachoyiannopoulos PG, Tzioufas AG. *COVID-19 Immunobiology: Lessons Learned, New Questions Arise*. **Front Immunol**. 2021 Aug 26; 12: 719023. **IF: 8.786**
58. Pezoulas VC, Hazapis O, Lagopati N, Exarchos TP, Goules AV, Tzioufas AG, Fotiadis DI, Stratis IG, Yannacopoulos AN, **Gorgoulis VG**. *Machine Learning Approaches on High Throughput NGS Data to Unveil Mechanisms of Function in Biology and Disease*. **Cancer Genomics Proteomics**. 2021 Sep-Oct; 18(5): 605-626. **IF: 3.395**
59. Veroutis D, Kouroumalis A, Lagopati N, Polyzou A, Chamilos C, Papadodima S, Evangelou K, **Gorgoulis VG**, Kletsas D. *Evaluation of senescent cells in intervertebral discs by lipofuscin staining*. **Mech Ageing Dev**. 2021 Aug 30; 199: 111564. **IF: 5.498**

60. Papaspyropoulos A, Lagopati N, Mourkioti I, Angelopoulou A, Kyriazis S, Lontos M, **Gorgoulis V***, Kotsinas A*. *Regulatory and Functional Involvement of Long Non-Coding RNAs in DNA Double-Strand Break Repair Mechanisms*. **Cells**. 2021 Jun 15;10(6):1506. (*co-correspondance) **IF: 7.666**
61. Belogiannis K, Florou VA, Fragkou PC, Ferous S, Chatzis L, Polyzou A, Lagopati N, Vassilakos D, Kittas C, Tzioufas AG, Tsiodras S, Sourvinos G, **Gorgoulis VG**. *SARS-CoV-2 Antigenemia as a Confounding Factor in Immunodiagnostic Assays: A Case Study*. **Viruses**. 2021 Jun 14;13(6):1143. **IF: 5.818**
62. Mathiasen SL, Gall-Mas L, Pateras IS, Theodorou SDP, Namini MRJ, Hansen MB, Martin OCB, Vadivel CK, Ntostoglou K, Butter D, Givskov M, Geisler C, Akbar AN, **Gorgoulis VG**, Frisan T, Ødum N, Krejsgaard T. *Bacterial genotoxins induce T cell senescence*. **Cell Rep**. 2021 Jun 8;35(10):109220. **IF: 9.995**
63. Chatzis L, Goules AV, Pezoulas V, Baldini C, Gandolfo S, Skopouli FN, Exarchos TP, Kapsogeorgou EK, Donati V, Voulgari PV, Mavragani CP, **Gorgoulis V**, De Vita S, Fotiadis D, Voulgarelis M, Moutsopoulos HM, Tzioufas AG. *A biomarker for lymphoma development in Sjogren's syndrome: Salivary gland focus score*. **Journal of Autoimmunity** 2021; 121: 102648. **IF: 14.511**
64. Lagopati N, Kotsinas A, Veroutis D, Evangelou K, Papaspyropoulos A, Arfanis M, Falaras P, Kitsiou PV, Pateras I, Bergonzini A, Frisan T, Kyriazis S, Tsoukleris DS, Tsilibary EC, Gazouli M, Pavlatou EA, **Gorgoulis VG**. *Biological Effect of Silver-modified Nanostructured Titanium Dioxide in Cancer*. **Cancer Genomics Proteomics**. 2021 May-Jun;18(3 Suppl):425-439. **IF: 3.395**
65. Venkatesan S, Angelova M, Hynds RE, Lu W-T, Dietzen M, Galanos P, Evangelou K, Lim EL, Nigro E, Watkins TBK, Rowan A, Ngo B, Bellelli R, Zalmas L-P, Zhai H, Campbell BB, Hobor S, Grönroos E, Jamal-Hanjani M, Santoni-Rugiu E, Bertoli C, Fenton TR, Janes SM, de Bruin RAM, Brown WL, Harris RS, **Gorgoulis VG**, McGranahan N, Bartkova J, Bakhoun SF, Bartek J, Kanu N, Swanton C. *Induction of APOBEC3 gene expression in pre-invasive disease promotes chromosomal instability early in cancer evolution*. **Cancer Disc** 2021 Oct;11(10):2456-2473. **IF: 38.272**
66. Spyropoulou Z, Papaspyropoulos A, Lagopati N, Myrianthopoulos V, Georgakilas AG, Fousteri M, Kotsinas A, **Gorgoulis VG**. *Cockayne Syndrome Group B (CSB): The regulatory frame-work governing the multifunctional protein and its plausible role in cancer*. **Cells**. 2021 Apr 10;10(4):866. **IF: 7.666**
67. Kohli J, Wang B, Brandenburg S, Basisty N, Evangelou K, Varela Erin M, Campisi J, Schilling B, **Gorgoulis V***, Demaria M*. *Algorithmic assessment of cellular senescence in experimental and clinical specimens*. **Nature Protocols** 2021 May;16(5):2471-2498. (*co-correspondance) **IF: 17.021**
68. Martin OCB, Bergonzini A, Lopez Chiloeches M, Paparouna E, Butter D, Theodorou SDP, Haykal MM, Boutet-Robinet E, Tebaldi T, Wakeham A, Rhen M, **Gorgoulis VG**, Mak T, Pateras IS, Frisan T. *Influence of the microenvironment on modulation of the host response by typhoid toxin*. **Cell Rep**. 2021 Apr 6;35(1):108931. **IF: 9.995**
69. van Vliet T, Varela-Eirin M, Wang B, Borghesan M, Brandenburg SM, Franzin R, Evangelou K, Seelen M, **Gorgoulis V**, Demaria M. *Physiological hypoxia restrains the senescence-associated secretory phenotype via AMPK-mediated mTOR suppression*. **Mol Cell** 2021b Mar 27:S1097-2765(21)00213-6. **IF: 19.328**
70. Moustakas II, Katsarou A, Legaki AI, Pyrina I, Ntostoglou K, Papatheodoridi AM, Gercken B, Pateras IS, **Gorgoulis VG**, Koutsilieris M, Chavakis T, Chatzigeorgiou A. *Hepatic Senescence Accompanies the Development of NAFLD in Non-Aged Mice Independently of Obesity*. **Int J Mol Sci**. 2021 Mar 26;22(7):3446. **IF: 6.208**

71. Tremi I, Havaki S, Georgitsopoulou S, Lagopati N, Georgakilas V, **Gorgoulis VG**, Georgakilas AG. *A Guide for Using Transmission Electron Microscopy for Studying the Radiosensitizing Effects of Gold Nanoparticles In Vitro*. **Nanomaterials** (Basel). 2021 Mar 27;11(4):859. **IF: 5.719**
72. Barbouti A, Lagopati N, Veroutis D, Goulas V, Evangelou K, Kanavaros P, **Gorgoulis VG**, Galaris D. *Implication of Dietary Iron-Chelating Bioactive Compounds in Molecular Mechanisms of Oxidative Stress-Induced Cell Ageing*. **Antioxidants** (Basel). 2021 Mar 21;10(3):491. **IF: 7.675**
73. Lagopati N, Belogiannis K, Angelopoulou A, Papaspyropoulos A, **Gorgoulis V**. *Non-Canonical Functions of the ARF Tumor Suppressor in Development and Tumorigenesis*. **Biomolecules**. 2021 Jan 12;11(1):86. **IF: 6.064**
74. Lagopati N, Evangelou K, Falaras P, Tsilibary EC, Vasileiou PVS, Havaki S, Angelopoulou A, Pavlatou EA, **Gorgoulis VG**. *Nanomedicine: Photo-activated nanostructured titanium dioxide, as a promising anticancer agent*. **Pharmacol Ther**. 2021 Dec 24;222:107795. **IF: 13.400**
75. Vergetis V, Skaltsas D, **Gorgoulis VG**, Tsirigos A. *Assessing drug development risk using Big Data and Machine Learning*. **Cancer Res**. 2021 Dec 22:canres.0866.2021. **IF: 13.312**
76. Lagopati N, Tsioli P, Mourkioti I, Polyzou A, Papaspyropoulos A, Zafiropoulos A, Evangelou K, Sourvinos G, **Gorgoulis VG**. *Sample pooling strategies for SARS-CoV-2 detection*. **J Virol Methods**. 2021 Mar; 289:114044. **IF: 2.623**
77. Koutsoudaki PN, Papadopoulos D, Passias P-G, Koutsoudaki P, **Gorgoulis VG**. *Cellular Senescence and Failure of Myelin Repair in Multiple Sclerosis*. **Mech Ageing Dev**. 2020 Jun 30;14:178. **IF: 5.498**
78. Papadopoulos D, Magliozzi R, Mitsikostas DD, **Gorgoulis VG**, Nicholas RS. *Aging, Cellular Senescence, and Progressive Multiple Sclerosis*. **Front Cell Neurosci**. 2020 Jun 30;14:178. **IF: 6.147**
79. Papalampros A, Vailas M, Ntostoglou K, Chiloeches ML, Sakellariou S, Chouliari NV, Samaras MG, Veltsista PD, Theodorou SDP, Margetis AT, Bergonzini A, Karydakis L, Hasemaki N, Havaki S, Moustakas II, Chatzigeorgiou A, Karamitros T, Patsea E, Kittas C, Lazaris AC, Felekouras E, **Gorgoulis VG**, Frisan T, Pateras IS. *Unique Spatial Immune Profiling in Pancreatic Ductal Adenocarcinoma with Enrichment of Exhausted and Senescent T Cells and Diffused CD47-SIRPa Expression*. **Cancers** (Basel). 2020 Jul 7;12(7):E1825. **IF: 6.575**
80. Magkouta SF, Pappas AG, Vaitsi PC, Agioutantis PC, Pateras IS, Moschos CA, Iliopoulou MP, Kosti CN, Loutrari HV, **Gorgoulis VG**, Kalomenidis IT. *MTH1 Favors Mesothelioma Progression and Mediates Paracrine Rescue of Bystander Endothelium From Oxidative Damage*. **JCI Insight**. 2020 Jun 18;5(12):134885. **IF: 9.484**
81. Azazmeh N, Assouline B, Winter E, Rupp S, Nevo Y, Maly A, Meir K, Witkiewicz AK, Cohen J, Rizou SV, Pikarsky E, Luxenburg C, **Gorgoulis VG**, Ben-Porath I. *Chronic expression of p16^{INK4a} in the epidermis induces Wnt-mediated hyperplasia and promotes tumor initiation*. **Nat Commun**. 2020a Jun 1;11(1):2711. **IF: 17.694**
82. Vougas K, Almpanis S, **Gorgoulis V**. *Deep learning: shaping the medicine of tomorrow*. **Mol Cell Oncol**. 2020 Feb 19;7(3):1723462. **IF: 1.420**
83. Karageorgiadi DM, Tsilimigras DI, Selemenakis P, Vlachou V, de Lastic AL, Rodi M, Chatziathanasiou D, Savvatakis K, Antoniou N, Deli AC, Papalampros A, Filis KA, Mouzaki A, Varvarigou A, Zografos G, **Gorgoulis VG**, Pateras IS, Sigala F. *Conditioning attenuates kidney and heart injury in rats following transient suprarenal occlusion of the abdominal aorta*. **Sci Rep**. 2020 Mar 19;10(1):5040. **IF: 4.996**

84. Moukengue B, Brown HK, Charrier C, Battaglia S, Baud'huin M, Quillard T, Pham TM, Pateras IS, **Gorgoulis VG**, Helleday T, Heymann D, Berglund UW, Ory B, Lamoureux F. *TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model*. **EBioMedicine**. 2020 Mar 6;53:102704. **IF: 11.205**
85. Raftopoulou C, Roumelioti FM, Dragona E, Gimelli S, Sloan-Béna F, **Gorgoulis V**, Antonarakis SE, Gagos S. *Karyotypic Flexibility of the Complex Cancer Genome and the Role of Polyploidization in Maintenance of Structural Integrity of Cancer Chromosomes*. **Cancers** (Basel). 2020 Mar 5;12(3). pii: E591. **IF: 6.575**
86. Barbouti A, Vasileiou PVS, Evangelou K, Vlasis KG, Papoudou-Bai A, **Gorgoulis VG**, Kanavaros P. *Implications of Oxidative Stress and Cellular Senescence in Age-Related Thymus Involution*. **Oxid Med Cell Longev**. 2020 Feb 5;2020:7986071. **IF: 7.310**
87. Georgila K, Gounis M, Havaki S, **Gorgoulis VG**, Eliopoulos AG. *mTORC1-dependent protein synthesis and autophagy uncouple in the regulation of Apolipoprotein A-I expression*. **Metabolism**. 2020 Apr;105:154186. **IF: 13.934**
88. Vakrakou AG, Svolaki IP, Evangelou K, **Gorgoulis VG**, Manoussakis MN. *Cell-autonomous epithelial activation of AIM2 (absent in melanoma-2) inflammasome by cytoplasmic DNA accumulations in primary Sjögren's syndrome*. **J Autoimmun**. 2020 Jan 6:102381. **IF: 14.511**
89. Goulielmaki E, Ioannidou A, Tsekrekou M, Stratigi K, Poutakidou IK, Gkirtzimanaki K, Aivaliotis M, Evangelou K, Topalis P, Altmüller J, **Gorgoulis VG**, Chatzinikolaou G, Garinis GA. *Tissue-infiltrating macrophages mediate an exosome-based metabolic reprogramming upon DNA damage*. **Nat Commun**. 2020b Jan 2;11(1):42. **IF: 17.694**
90. Antoniou N, Lagopati N, Balourdas DI, Nikolaou M, Papalampros A, Vasileiou PVS, Myrianthopoulos V, Kotsinas A, Shiloh Y, Lontos M, **Gorgoulis VG**. *The Role of E3, E4 Ubiquitin Ligase (UBE4B) in Human Pathologies*. **Cancers** (Basel). 2019 Dec 24;12(1). pii: E62. **IF: 6.575**
91. Sakellaropoulos T, Vougas K, Narang S, Koinis F, Kotsinas A, Polyzos A, Moss TJ, Piha-Paul S, Zhou H, Kardala E, Damianidou E, Alexopoulos LG, Aifantis I, Townsend PA, Panayiotidis MI, Sfrikakis P, Bartek J, Fitzgerald RC, Thanos D, Mills Shaw KR, Petty R, Tsirigos A, **Gorgoulis VG**. *A Deep Learning Framework for Predicting Response to Therapy in Cancer*. **Cell Rep**. 2019 Dec 10;29(11):3367-3373.e4. **IF: 9.995**
92. **Gorgoulis V**, Adams PD, Alimonti A, Bennett DC, Bischof O, Bishop C, Campisi J, Collado M, Evangelou K, Ferbeyre G, Gil J, Hara E, Krizhanovsky V, Jurk D, Maier AB, Narita M, Niedernhofer L, Passos JF, Robbins PD, Schmitt CA, Sedivy J, Vougas K, von Zglinicki T, Zhou D, Serrano M, Demaria M. *Cellular Senescence: Defining a Path Forward*. **Cell**. 2019 Oct 31;179(4):813-827. **IF: 66.850**
93. Vanzo R, Bartkova J, Merchut-Maya JM, Hall A, Bouchal J, Dyrskjøt L, Frankel LB, **Gorgoulis V**, Maya-Mendoza A, Jäättelä M, Bartek J. *Autophagy role(s) in response to oncogenes and DNA replication stress*. **Cell Death Differ**. 2019 Aug 14. doi: 10.1038/s41418-019-0403-9. **IF: 12.067**
94. Vougas K, Sakellaropoulos T, Kotsinas A, Foukas GP, Ntargaras A, Koinis F, Polyzos A, Myrianthopoulos V, Zhou H, Narang S, Georgoulis V, Alexopoulos L, Aifantis I, Townsend PA, Sfrikakis P, Fitzgerald R, Thanos D, Bartek J, Petty R, Tsirigos A, **Gorgoulis VG**. *Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining*. **Pharmacol Ther**. 2019 Jul 30:107395. **IF: 13.400**

95. Harvati K, Röding C, Bosman AM, Karakostis FA, Grün R, Stringer C, Karkanias P, Thompson NC, Koutoulidis V, Mouloupoulos LA, **Gorgoulis VG**, Kouloukoussa M. *Apidima Cave fossils provide earliest evidence of Homo sapiens in Eurasia*. **Nature**. 2019 Jul;571(7766):500-504. **IF: 69.504**
96. Vasileiou PVS, Evangelou K, Vlasis K, Fildisis G, Panayiotidis MI, Chronopoulos E, Passias PG, Kouloukoussa M, **Gorgoulis VG**, Havaki S. *Mitochondrial Homeostasis and Cellular Senescence*. **Cells**. 2019 Jul 6;8(7). pii: E686. **IF: 7.666**
97. Economopoulou P, Koutsodontis G, Avgeris M, Strati A, Kroupis C, Pateras I, Kirodimos E, Giotakis E, Kotsantis I, Maragoudakis P, **Gorgoulis V**, Scorilas A, Lianidou E, Psyrris A. *HPV16 E6/E7 expression in circulating tumor cells in oropharyngeal squamous cell cancers: A pilot study*. **PLoS One**. 2019 May 9;14(5):e0215984. **IF: 3.752**
98. Tsakiri EN, Gumeni S, Vougas K, Pendin D, Papassideri I, Daga A, **Gorgoulis V**, Juhász G, Scorrano L, Trougakos IP. *Proteasome dysfunction induces excessive proteome instability and loss of mitostasis that can be mitigated by enhancing mitochondrial fusion or autophagy*. **Autophagy**. 2019 Apr 19:1-17. **IF: 13.391**
99. Pappas AG, Magkouta S, Pateras IS, Skianis I, Moschos C, Vazakidou ME, Psarra K, **Gorgoulis VG**, Kalomenidis I. *Versican modulates tumor-associated macrophage properties to stimulate mesothelioma growth*. **Oncoimmunology**. 2018 Nov 2;8(2):e1537427. **IF: 7.723**
100. Tsakiri EN, Gumeni S, Iliaki KK, Benaki D, Vougas K, Sykiotis GP, **Gorgoulis VG**, Mikros E, Scorrano L, Trougakos IP. *Hyperactivation of Nrf2 increases stress tolerance at the cost of aging acceleration due to metabolic deregulation*. **Aging Cell**. 2018 Dec 10:e12845. **IF: 11.005**
101. Lobachevsky PN, Ventura J, Giannakandropoulou L, Forrester H, Palazzolo JS, Haynes NM, Stevenson AW, Hall CJ, Mason J, Pollakis G, Pateras IS, **Gorgoulis V**, Terzoudi GI, Hamilton JA, Sprung CN, Georgakilas AG, Martin OA. *A Functional Immune System Is Required For The Systemic Genotoxic Effects Of Localised Irradiation*. **Int J Radiat Oncol Biol Phys**. 2018 Dec 6. pii: S0360-3016(18)34068-9. **IF: 8.013**
102. **Gorgoulis VG**, Kotsinas A. *Cura"x"ing Cancer and Beyond*. **Bioessays**. 2018 Dec 3:e1800223. **IF: 4.653**
103. Cooks T, Theodorou SD, Paparouna E, Rizou SV, Myrianthopoulos V, **Gorgoulis VG**, Pateras IS. *Immunohisto(cyto)chemistry: an old time classic tool driving modern oncological therapies*. **Histol Histopathol**. 2018 Nov 27:18069. doi: 10.14670/HH-18-069. **IF: 2.130**
104. Rizou SV, Evangelou K, Myrianthopoulos V, Mourouzis I, Havaki S, Athanasiou A, Vasileiou PVS, Margetis A, Kotsinas A, Kastrinakis NG, Sfikakis P, Townsend P, Mikros E, Pantos C, **Gorgoulis VG**. *A Novel Quantitative Method for the Detection of Lipofuscin, the Main By-Product of Cellular Senescence, in Fluids*. **Methods Mol Biol**. 2019;1896:119-138. **IF: 1.370**
105. Furth N, Pateras IS, Rotkopf R, Vlachou V, Rivkin I, Schmitt I, Bakaev D, Gershoni A, Ainbinder E, Leshkowitz D, Johnson RL, **Gorgoulis VG**, Oren M, Aylon Y. *LATS1 and LATS2 suppress breast cancer progression by maintaining cell identity and metabolic state*. **Life Sci Alliance**. 2018 Oct 30;1(5):e201800171. **IF: 5.781**
106. Lallo A, Gulati S, Schenk MW, Khandelwal G, Berglund UW, Pateras IS, Chester CPE, Pham TM, Kalderen C, Frese KK, **Gorgoulis VG**, Miller C, Blackhall F, Helleday T, Dive C. *Ex Vivo Culture of Cells Derived From Circulating Tumour Cell Xenograft to support Small Cell Lung Cancer Research and Experimental Therapeutics*. **Br J Pharmacol**. 2019 Feb;176(3):436-450 **IF: 9.473**

107. Kritsilis M, V Rizou S, Koutsoudaki PN, Evangelou K, **Gorgoulis VG**, Papadopoulos D. *Ageing, Cellular Senescence and Neurodegenerative Disease*. **Int J Mol Sci**. 2018 Sep 27;19(10). pii: E2937. **IF: 6.208**
108. Myriantopoulos V, Evangelou K, Vasileiou PVS, Cooks T, Vassilakopoulos TP, Pangalis GA, Kouloukoussa M, Kittas C, Georgakilas AG, **Gorgoulis VG**. *Senescence and senotherapeutics: a new field in cancer therapy*. **Pharmacol Ther**. 2018 Aug 16. pii: S0163-7258(18)30144-X. **IF: 13.400**
109. Champeris Tsaniras S, Villiou M, Giannou AD, Nikou S, Petropoulos M, Pateras IS, Tserou P, Karousi F, Lalioti ME, **Gorgoulis VG**, Patmanidi AL, Stathopoulos GT, Bravou V, Lygerou Z, Taraviras S. *Geminin ablation in vivo enhances tumorigenesis through increased genomic instability*. **J Pathol**. 2018 Oct;246(2):134-140. **IF: 9.883**
110. Pefani DE, Tognoli ML, Pirincci Ercan D, **Gorgoulis V**, O'Neill E. *MST2 kinase suppresses rDNA transcription in response to DNA damage by phosphorylating nucleolar histone H2B*. **EMBO J**. 2018 Aug 1;37(15). pii: e98760. **IF: 14.012**
111. Magkouta S, Pappas A, Pateras IS, Kollintza A, Moschos C, Vazakidou ME, Karavana V, **Gorgoulis VG**, Kalomenidis I. *Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications*. **Oncotarget**. 2018 Apr 24;9(31):21783-21796. **IF: 2.680**
112. **Gorgoulis VG**, Pefani DE, Pateras IS, Trougakos IP. *Integrating the DNA damage and protein stress responses during cancer development and treatment*. **J Pathol**. 2018 Sep;246(1):12-40. **IF: 9.883**
113. Galanos P, Pappas G, Polyzos A, Kotsinas A, Svolaki I, Giakoumakis NN, Glytsou C, Pateras IS, Swain U, Souliotis VL, Georgakilas AG, Geacintov N, Scorrano L, Lukas C, Lukas J, Livneh Z, Lygerou Z, Chowdhury D, Sørensen CS, Bartek J, **Gorgoulis VG**. *Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability*. **Genome Biol**. 2018 Mar 16;19(1):37. **IF: 17.906**
114. Barbouti A, Evangelou K, Pateras IS, Papoudou-Bai A, Patereli A, Stefanaki K, Rontogianni D, Muñoz-Espín D, Kanavaros P, **Gorgoulis VG**. *In situ evidence of cellular senescence in Thymic Epithelial Cells (TECs) during human thymic involution*. **Mech Ageing Dev**. 2018 Feb 25. pii: S0047-6374(17)30300-7. **IF: 5.498**
115. Cooks T, Pateras IS, Jenkins LM, Patel KM, Robles AI, Morris J, Forshew T, Appella E, **Gorgoulis VG**, Harris CC. *Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246*. **Nat Commun**. 2018 Feb 22;9(1):771. [co-senior: www.gorgoulis.gr] **IF: 17.694**
116. Solomon H, Dinowitz N, Pateras IS, Cooks T, Shetzer Y, Molchadsky A, Charni M, Rabani S, Koifman G, Tarcic O, Porat Z, Kogan-Sakin I, Goldfinger N, Oren M, Harris CC, **Gorgoulis VG**, Rotter V. *Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers*. **Oncogene**. 2018 Jan 18. **IF: 8.756**
117. Komseli ES, Pateras IS, Krejsgaard T, Stawiski K, Rizou SV, Polyzos A, Roumelioti FM, Chiourea M, Mourkioti I, Paparouna E, Zampetidis CP, Gumeni S, Trougakos IP, Pefani DE, O'Neill E, Gagos S, Eliopoulos AG, Fendler W, Chowdhury D, Bartek J, **Gorgoulis VG**. *A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced senescence*. **BMC Genomics**. 2018 Jan 10;19(1):37. **IF: 4.547**
118. Ventura J, Lobachevsky PN, Palazzolo JS, Forrester H, Haynes NM, Ivashkevich A, Stevenson AW, Hall CJ, Ntargaras A, Kotsaris V, Pollakis GC, Potsi G, Skordylis K, Terzoudi G, Pateras IS, **Gorgoulis VG**, Georgakilas AG, Sprung CN, Martin OA. *Localized Synchrotron Irradiation of Mouse Skin Induces Persistent Systemic*

- Genotoxic and Immune Responses*. **Cancer Res.** 2017 Nov 15;77(22):6389-6399. **IF: 13.312**
119. Myriantopoulos V, Lozach O, Zareifi D, Alexopoulos L, Meijer L, **Gorgoulis VG**, Mikros E. *Combined Virtual and Experimental Screening for CK1 Inhibitors Identifies a Modulator of p53 and Reveals Important Aspects of in Silico Screening Performance*. **Int J Mol Sci.** 2017 Oct 6;18(10). pii: E2102. **IF: 6.208**
120. Gumeni S, Evangelakou Z, **Gorgoulis VG**, Trougakos IP. *Proteome Stability as a Key Factor of Genome Integrity*. **Int J Mol Sci.** 2017 Sep 22;18(10). pii: E2036. **IF: 6.208**
121. Havaki S, Vlachou V, Zampetidis CP, Selemenakis P, Kotsinas A, Mavrogonatou E, Rizou SV, Kyrodimos E, Evangelou K, Kletsas D, Giatromanolaki A, **Gorgoulis VG**. *Monitoring Autophagy Immunohistochemically and Ultrastructurally during Human Head and Neck Carcinogenesis. Relationship with the DNA Damage Response Pathway*. **Int J Mol Sci.** 2017 Sep 7;18(9). pii: E1920. **IF: 6.208**
122. **Gorgoulis VG**, Pateras IS, Kotsinas A. *MiR-signing gastrointestinal (con-)tract cancer*. **Oncotarget.** 2017 May 2;8(18):29536-29537. **IF: 2.680**
123. Souli MP, Klonos P, Fragopoulou AF, Mavragani IV, Pateras IS, Kostomitsopoulos N, Margaritis LH, Zoumpoulis P, Kaklamanis L, Kletsas D, **Gorgoulis VG**, Kyritsis A, Pissis P, Georgakilas AG. *Applying Broadband Dielectric Spectroscopy (BDS) for the Biophysical Characterization of Mammalian Tissues under a Variety of Cellular Stresses*. **Int J Mol Sci.** 2017 Apr 15;18(4). **IF: 6.208**
124. Kalisperati P, Spanou E, Pateras IS, Korkolopoulou P, Varvarigou A, Karavokyros I, **Gorgoulis VG**, Vlachoyiannopoulos PG, Sougioultzis S. *Inflammation, DNA Damage, Helicobacter pylori and Gastric Tumorigenesis*. **Front Genet.** 2017 Feb 27;8:20. **IF: 4.772**
125. Evangelou K, Lougiakis N, Rizou SV, Kotsinas A, Kletsas D, Muñoz-Espín D, Kastrinakis NG, Pouli N, Marakos P, Townsend P, Serrano M, Bartek J, **Gorgoulis VG**. *Robust, universal biomarker assay to detect senescent cells in biological specimens*. **Aging Cell.** 2017 Feb;16(1):192-197. **IF: 11.005**
126. Tarcic O, Granit RZ, Pateras IS, Masury H, Maly B, Zwang Y, Yarden Y, **Gorgoulis VG**, Pikarsky E, Ben-Porath I, Oren M. *RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer*. **Cell Death Differ.** 2017 Apr;24(4):694-704. **IF: 12.067**
127. Herrtwich L, Nanda I, Evangelou K, Nikolova T, Horn V, Sagar, Erny D, Stefanowski J, Rogell L, Klein C, Gharun K, Follo M, Seidl M, Kremer B, Münke N, Senges J, Fliegau M, Aschman T, Pfeifer D, Sarrazin S, Sieweke MH, Wagner D, Dierks C, Haaf T, Ness T, Zaiss MM, Voll RE, Deshmukh SD, Prinz M, Goldmann T, Hölscher C, Hauser AE, Lopez-Contreras AJ, Grün D, **Gorgoulis V**, Diefenbach A, Henneke P, Triantafyllopoulou A. *DNA Damage Signaling Instructs Polyploid Macrophage Fate in Granulomas*. **Cell.** 2016 Nov 17;167(5):1264-1280.e18. **IF: 66.850**
128. Sotiriou SK, Kamileri I, Lugli N, Evangelou K, Da-Ré C, Huber F, Padayachy L, Tardy S, Nicati NL, Barriot S, Ochs F, Lukas C, Lukas J, **Gorgoulis VG**, Scapozza L, Halazonetis TD. *Mammalian RAD52 Functions in Break-Induced Replication Repair of Collapsed DNA Replication Forks*. **Mol Cell.** 2016 Dec 15;64(6):1127-1134. **IF: 19.328**
129. Kaffe E, Katsifa A, Xylourgidis N, Ninou I, Zannikou M, Harokopos V, Foka P, Dimitriadis A, Evangelou K, Moulas AN, Georgopoulou U, **Gorgoulis VG**, Dalekos GN, Aidinis V. *Hepatocyte autotaxin expression promotes liver fibrosis and cancer*. **Hepatology.** 2017 Apr;65(4):1369-1383. **IF: 17.298**

130. Galtsidis S, Logotheti S, Pavlopoulou A, Zampetidis CP, Papachristopoulou G, Scorilas A, Vojtesek B, **Gorgoulis V**, Zoumpourlis V. *Unravelling a p73-regulated network: The role of a novel p73-dependent target, MIR3158, in cancer cell migration and invasiveness*. **Cancer Lett.** 2017 Mar 1;388:96-106. **IF: 9.756**
131. Eliopoulos AG, Havaki S, **Gorgoulis VG**. *DNA Damage Response and Autophagy: A Meaningful Partnership*. **Front Genet.** 2016 Nov 21;7:204. **IF: 4.772**
132. Evangelou K, Galanos P, **Gorgoulis VG**. *The Janus face of p21*. **Mol Cell Oncol.** 2016 Jul 29;3(5):e1215776. **IF: 1.420**
133. Warpman Berglund U, Sanjiv K, Gad H, Kalderén C, Koolmeister T, Pham T, Gokturk C, Jafari R, Maddalo G, Seashore-Ludlow B, Chernobrovkin A, Manoilov A, Pateras IS, Rasti A, Jemth AS, Almlöf I, Loseva O, Visnes T, Einarsdottir BO, Gaugaz FZ, Saleh A, Platzack B, Wallner OA, Vallin KS, Henriksson M, Wakchaure P, Borhade S, Herr P, Kallberg Y, Baranczewski P, Homan EJ, Wiita E, Nagpal V, Meijer T, Schipper N, Rudd SG, Bräutigam L, Lindqvist A, Filppula A, Lee TC, Artursson P, Nilsson JA, **Gorgoulis VG**, Lehtiö J, Zubarev RA, Scobie M, Helleday T. *Validation and development of MTH1 inhibitors for treatment of cancer*. **Ann Oncol.** 2016 Dec;27(12):2275-2283. **IF: 51.769**
134. Evangelou K, **Gorgoulis VG**. *Sudan Black B, The Specific Histochemical Stain for Lipofuscin: A Novel Method to Detect Senescent Cells*. **Methods Mol Biol.** 2017 1534:111-119. **IF: 1.370**
135. Galanos P, Pappas G, **Gorgoulis VG**. *p21WAF1/Cip1 - PCNA: Fatal attraction*. **Cell Cycle.** 2016 Aug 11:1-2. **IF: 5.173**
136. Del Mare S, Husanie H, Iancu O, Abu-Odeh M, Evangelou K, Lovat F, Volinia S, Gordon J, Amir G, Stein JL, Stein GS, Croce CM, **Gorgoulis VG**, Lian JB, Aqeilan RI. *p53 and WWOX dysregulation synergize to drive the development of osteosarcoma*. **Cancer Res.** 2016 Aug 22. pii: canres.0621.2016. **IF: 13.312**
137. Moreno A, Carrington JT, Albergante L, Al Mamun M, Haagensen EJ, Komseli ES, **Gorgoulis VG**, Newman TJ, Blow JJ. *Unreplicated DNA remaining from unperturbed S phases passes through mitosis for resolution in daughter cells*. **Proc Natl Acad Sci U S A.** 2016 Aug 11. pii: 201603252. **IF: 12.779**
138. Souliotis VL, Vougas K, **Gorgoulis VG**, Sfikakis PP. *Defective DNA repair and chromatin organization in patients with quiescent systemic lupus erythematosus*. **Arthritis Res Ther.** 2016 Aug 4;18(1):182. **IF: 5.606**
139. Liakou E, Mavrogonatou E, Pratsinis H, Rizou S, Evangelou K, Panagiotou PN, Karamanos NK, **Gorgoulis VG**, Kletsas D. *Ionizing radiation-mediated premature senescence and paracrine interactions with cancer cells enhance the expression of syndecan 1 in human breast stromal fibroblasts: the role of TGF- β* . **Aging** (Albany NY). 2016 Aug;8(8):1650-69. **IF: 5.955**
140. Galanos P, Vougas K, Walter D, Polyzos A, Maya-Mendoza A, Haagensen EJ, Kokkalis A, Roumelioti FM, Gagos S, Tzetis M, Canovas B, Igea A, Ahuja AK, Zellweger R, Havaki S, Kanavakis E, Kletsas D, Roninson IB, Garbis SD, Lopes M, Nebreda A, Thanos D, Blow JJ, Townsend P, Sørensen CS, Bartek J, **Gorgoulis VG**. *Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing*. **Nat Cell Biol.** 2016 Jul;18(7):777-89. **IF: 28.213**
141. Georgakilas AG, **Gorgoulis VG**. *Systemic dna damage: Mechanisms, effects and mitigation strategies*. **Semin Cancer Biol.** 2016 Jun;37-38:1-2. **IF: 17.012**
142. Logotheti S, Khoury N, Vlahopoulos SA, Skourti E, Papaevangelidou D, Liloglou T, **Gorgoulis V**, Budunova I, Kyriakopoulos AM, Zoumpourlis V. *N-bromotaurine surrogates for loss of antiproliferative response and enhances cisplatin efficacy in*

- cancer cells with impaired glucocorticoid receptor. Transl Res.* 2016 Jul;173:58-73.e2 **IF: 10.171**
143. Georgakopoulou E, Evangelou K, Havaki S, Townsend P, Kanavaros P, **Gorgoulis VG**. *Apoptosis or senescence? Which exit route do epithelial cells and fibroblasts preferentially follow? Mech Ageing Dev.* 2016 Jun;156:17-24. **IF: 5.498**
144. Del Bel Belluz L, Guidi R, Pateras IS, Levi L, Mihaljevic B, Rouf SF, Wrande M, Candela M, Turrone S, Nastasi C, Consolandi C, Peano C, Tebaldi T, Viero G, **Gorgoulis VG**, Krejsgaard T, Rhen M, Frisan T. *The Typhoid Toxin Promotes Host Survival and the Establishment of a Persistent Asymptomatic Infection. PLoS Pathog.* 2016 Apr 7;12(4):e1005528. **IF: 7.464**
145. Tarcic O, Pateras IS, Cooks T, Shema E, Kanterman J, Ashkenazi H, Boocholez H, Hubert A, Rotkopf R, Baniyash M, Pikarsky E, **Gorgoulis VG**, Oren M. RNF20 Links Histone H2B Ubiquitylation with Inflammation and Inflammation-Associated Cancer. **Cell Rep.** 2016 Feb 16;14(6):1462-76. **IF: 9.995**
146. Walter D, Hoffmann S, Komseli ES, Rappsilber J, **Gorgoulis V**, Sørensen CS. *SCF(Cyclin F)-dependent degradation of CDC6 suppresses DNA re-replication. Nat Commun.* 2016 Jan 28;7:10530. **IF: 17.694**
147. Petrakis TG, Komseli ES, Papaioannou M, Vougas K, Polyzos A, Myriantopoulos V, Mikros E, Trougakos IP, Thanos D, Branzei D, Townsend P, **Gorgoulis VG**. *Exploring and exploiting the systemic effects of deregulated replication licensing. Semin Cancer Biol.* 2015 Dec 17. pii: S1044-579X(15)30003-1. **IF: 17.012**
148. Skourti E, Logotheti S, Kontos CK, Pavlopoulou A, Dimoragka PT, Trougakos IP, **Gorgoulis V**, Scorilas A, Michalopoulos I, Zoumpourlis V. *Progression of mouse skin carcinogenesis is associated with the orchestrated deregulation of miR-200 family members, miR-205 and their common targets. Mol Carcinog.* 2015 Aug 27. **IF: 5.139**
149. Golomb L, Sagiv A, Pateras IS, Maly A, Krizhanovsky V, **Gorgoulis VG**, Oren M, Ben-Yehuda A. *Age-associated inflammation connects RAS-induced senescence to stem cell dysfunction and epidermal malignancy. Cell Death Differ.* 2015 Nov;22(11):1764-74. **IF: 12.067**
150. Bahri R, Pateras IS, D'Orlando O, Goyeneche-Patino DA, Campbell M, Polansky JK, Sandig H, Papaioannou M, Evangelou K, Foukas PG, **Gorgoulis VG**, Bulfone-Paus S. *IL-15 suppresses colitis-associated colon carcinogenesis by inducing antitumor immunity. Oncoimmunology.* 2015 Jan 22;4(9):e1002721. **IF: 7.723**
151. Kotsinas A, Sigala F, Garbis SD, Galyfos G, Filis K, Vougas K, Papalampros A, Johnson EE, Chronopoulos E, Georgakilas AG, **Gorgoulis VG**. *MicroRNAs Determining Inflammation as Novel Biomarkers and Potential Therapeutic Targets. Curr Med Chem.* 2015;22(22):2666-79. **IF: 4.740**
152. Pateras IS, Havaki S, Nikitopoulou X, Vougas K, Townsend PA, Panayiotidis MI, Georgakilas AG, **Gorgoulis VG**. *The DNA damage response and immune signaling alliance: Is it good or bad? Nature decides when and where. Pharmacol Ther.* 2015 Oct;154:36-56. **IF: 13.400**
153. Zeidan B, Jackson TR, Larkin SE, Cutress RI, Coulton GR, Ashton-Key M, Murray N, Packham G, **Gorgoulis V**, Garbis SD, Townsend PA. *Annexin A3 is a mammary marker and a potential neoplastic breast cell therapeutic target. Oncotarget.* 2015 Aug 28;6(25):21421-7. **IF: 2.680**
154. Gupta J, Igea A, Papaioannou M, Lopez-Casas PP, Llonch E, Hidalgo M, **Gorgoulis VG**, Nebreda AR. *Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors. Oncotarget.* 2015 Apr 20;6(11):8539-51. **IF: 2.680**

155. Kalousi A, Hoffbeck AS, Selemenakis PN, Pinder J, Savage KI, Khanna KK, Brino L, Dellaire G, **Gorgoulis VG**, Soutoglou E. *The nuclear oncogene SET controls DNA repair by KAP1 and HP1 retention to chromatin.* **Cell Rep.** 2015 Apr 7;11(1):149-63. **IF: 9.995**
156. Armakolas A, Kaparelou M, Dimakakos A, Papageorgiou E, Armakolas N, Antonopoulos A, Petraki C, Lekarakou M, Lelovas P, Stathaki M, Donta I, Galanos PS, Msaouel P, **Gorgoulis VG**, Koutsilieris M. *Oncogenic role of the Ec peptide of the IGF-1Ec isoform in prostate.* **Mol Med.** 2015 Jan 6;21:167-79. **IF: 6.376**
157. Georgakilas AG, Tsantoulis P, Kotsinas A, Michalopoulos I, Townsend P, **Gorgoulis VG**. *Are common fragile sites merely structural domains or highly organized "functional" units susceptible to oncogenic stress?* **Cell Mol Life Sci.** 2014 Dec;71(23):4519-44. **IF: 9.207**
158. Atsaves V, Lekakis L, Drakos E, Leventaki V, Ghaderi M, Baltatzis GE, Chioureas D, Jones D, Feretzaki M, Liakou C, Panayiotidis P, **Gorgoulis V**, Patsouris E, Medeiros LJ, Claret FX, Rassidakis GZ. *The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.* **Br J Haematol.** 2014 Nov;167(4):514-23. **IF: 8.615**
159. Kotsinas A, Papanagnou P, Evangelou K, Trigas GC, Kostourou V, Townsend P, **Gorgoulis VG**. *ARF: a versatile DNA damage response ally at the crossroads of development and tumorigenesis.* **Front Genet.** 2014 Jul 22;5:236. doi: 10.3389/fgene.2014.00236. **IF: 4.772**
160. Gupta J, Del Barco Barrantes I, Igea A, Sakellariou S, Pateras IS, **Gorgoulis VG**, Nebreda AR. *Dual Function of p38α MAPK in Colon Cancer: Suppression of Colitis-Associated Tumor Initiation but Requirement for Cancer Cell Survival.* **Cancer Cell.** 2014 Apr 14;25(4):484-500. **IF: 38.585**
161. Kotsinas A, Papanagnou P, Galanos P, Schramek D, Townsend P, Penninger JM, Bartek J, **Gorgoulis VG**. *MKK7 and ARF: New players in the DNA damage response scenery.* **Cell Cycle.** 2014 Apr 15;13(8):1227-36. **IF: 5.173**
162. Ogrunc M, Di Micco R, Liontos M, Bombardelli L, Mione M, Fumagalli M, **Gorgoulis VG**, d'Adda di Fagagna F. *Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation.* **Cell Death Differ.** 2014 Jun;21(6):998-1012. **IF: 12.067**
163. Havaki S, Kotsinas A, Chronopoulos E, Kletsas D, Georgakilas A, **Gorgoulis VG**. *The role of oxidative DNA damage in radiation induced bystander effect.* **Cancer Lett.** 2015 Jan 1;356(1):43-51. **IF: 9.756**
164. Ragin C, Obikoya-Malomo M, Kim S, Chen Z, Flores-Obando R, Gibbs D, Koriyama C, Aguayo F, Koshiol J, Caporaso NE, Carpagnano GE, Ciotti M, Dosaka-Akita H, Fukayama M, Goto A, Spandidos DA, **Gorgoulis V**, Heideman DA, van Boerdonk RA, Hiroshima K, Iwakawa R, Kastrinakis NG, Kinoshita I, Akiba S, Landi MT, Eugene Liu H, Wang JL, Mehra R, Khuri FR, Lim WT, Owonikoko TK, Ramalingam S, Sarchianaki E, Syrjanen K, Tsao MS, Sykes J, Hee SW, Yokota J, Zaravinos A, Taioli E. *HPV-associated lung cancers: an international pooled analysis.* **Carcinogenesis.** 2014 Jun;35(6):1267-75. **IF: 4.741**
165. Kefala M, Papageorgiou SG, Kontos CK, Economopoulou P, Tsanas A, Pappa V, Panayiotides IG, **Gorgoulis VG**, Patsouris E, Foukas PG. *Increased expression of phosphorylated NBS1, a key molecule of the DNA damage response machinery, is an adverse prognostic factor in patients with de novo myelodysplastic syndromes.* **Leuk Res.** 2013 Nov;37(11):1576-82. **IF: 3.715**
166. Paschalaki KE, Starke RD, Hu Y, Mercado N, Margariti A, **Gorgoulis VG**, Randi AM, Barnes PJ. *Dysfunction of endothelial progenitor cells from smokers and chronic*

- obstructive pulmonary disease patients due to increased DNA damage and senescence. Stem Cells.* 2013 Dec;31(12):2813-26. **IF: 5.845**
167. Velimezi G, Lontos M, Vougas K, Roumeliotis T, Bartkova J, Sideridou M, Dereli-Oz A, Kocylowski M, Pateras IS, Evangelou K, Kotsinas A, Orsolich I, Bursac S, Cokaric-Brdovcak M, Zoumpourlis V, Kletsas D, Papafotiou G, Klinakis A, Volarevic S, Gu W, Bartek J, Halazonetis TD, **Gorgoulis VG.** *Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer. Nat Cell Biol.* 2013 Aug;15(8):967-77. **IF: 28.213**
168. Evangelou K, Bartkova J, Kotsinas A, Pateras IS, Lontos M, Velimezi G, Kosar M, Liloglou T, Trougakos IP, Dyrskjot L, Andersen CL, Papaioannou M, Drosos Y, Papafotiou G, Hodny Z, Sosa-Pineda B, Wu XR, Klinakis A, Orntoft T, Lukas J, Bartek J, **Gorgoulis VG.** *The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis. Cell Death Differ.* 2013 Nov;20(11):1485-97. doi: 10.1038/cdd.2013.76. **IF: 12.067**
169. Tsakiri EN, Sykiotis GP, Papassideri IS, **Gorgoulis VG,** Bohmann D, Trougakos IP. *Differential regulation of proteasome functionality in reproductive vs. somatic tissues of Drosophila during aging or oxidative stress. FASEB J* 2013 Jun; 27(6):2407-20. **IF: 5.834**
170. Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N, Harpaz N, Itzkowitz S, Harris CC, Rotter V, **Gorgoulis VG,** Oren M. *Mutant p53 prolongs NF- κ B activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell.* 2013 May 13;23(5):634-46. **IF: 38.585**
171. Gkirtzimanaki K, Gkouskou KK, Oleksiewicz U, Nikolaidis G, Vyrla D, Lontos M, Pelekanou V, Kanellis DC, Evangelou K, Stathopoulos EN, Field JK, Tschlis PN, **Gorgoulis V,** Liloglou T, Eliopoulos AG. *TPL2 kinase is a suppressor of lung carcinogenesis. Proc Natl Acad Sci U S A.* 2013 Apr 16;110(16):E1470-9. **IF: 12.779**
172. Trougakos IP, Sesti F, Tsakiri E, **Gorgoulis VG.** *Non-enzymatic post-translational protein modifications and proteostasis network deregulation in carcinogenesis. J Proteomics.* 2013 Oct 30;92:274-98. **IF: 3.855**
173. Tsakiri EN, Sykiotis GP, Papassideri IS, Terpos E, Dimopoulos MA, **Gorgoulis VG,** Bohmann D, Trougakos IP. *Proteasome dysfunction in Drosophila signals to an Nrf2-dependent regulatory circuit aiming to restore proteostasis and prevent premature aging. Aging Cell.* 2013 Oct;12(5):802-13. **IF: 11.005**
174. Georgakopoulou EA, Tsimaratou K, Evangelou K, Fernandez Marcos PJ, Zoumpourlis V, Trougakos IP, Kletsas D, Bartek J, Serrano M, **Gorgoulis VG.** *Specific lipofuscin staining as a novel biomarker to detect replicative and stress-induced senescence. A method applicable in cryo-preserved and archival tissues. Aging (Albany NY).* 2013 Jan;5(1):37-50. **IF: 5.955**
175. Kritikos O, Tsagarakis M, Tsoutsos D, Kittas C, **Gorgoulis V,** Papalois A, Giannopoulos A, Kakiopoulos G, Papadopoulos O. *The efficacy of recombinant human activated protein C (rhAPC) vs antithrombin III (at III) vs heparin, in the healing process of partial-thickness burns: a comparative study. Ann Burns Fire Disasters.* 2012 Jun 30;25(2):66-73. **IF: 0.67**
176. Nikolaev SI, Sotiriou SK, Pateras IS, Santoni F, Sougioultzis S, Edgren H, Almusa H, Robyr D, Guipponi M, Saarela J, **Gorgoulis VG,** Antonarakis SE, Halazonetis TD. *A single-nucleotide substitution mutator phenotype revealed by exome sequencing of human colon adenomas. Cancer Res.* 2012 Dec 1;72(23):6279-89. **IF: 13.312**

177. Logotheti S, Papaevangelidou D, Michalopoulos I, Sideridou M, Tsimaratou K, Christodoulou I, Pyrillou K, **Gorgoulis V**, Vlahopoulos S, Zoumpourlis V. *Progression of mouse skin carcinogenesis is associated with increased ER α levels and is repressed by a dominant negative form of ER α* . **PLoS One**. 2012;7(8):e41957. **IF: 3.752**
178. Salagianni M, Galani IE, Lundberg AM, Davos CH, Varela A, Gavriil A, Lyytikäinen LP, Lehtimäki T, Sigala F, Folkersen L, **Gorgoulis V**, Lenglet S, Montecucco F, Mach F, Hedin U, Hansson GK, Monaco C, Andreakos E. *Toll-like receptor 7 protects from atherosclerosis by constraining "inflammatory" macrophage activation*. **Circulation** 2012 Aug 21;126(8):952-62. **IF: 39.918**
179. Petrakis TG, Vougas K, **Gorgoulis VG**. *Cdc6: a multi-functional molecular switch with critical role in carcinogenesis*. **Transcription**. 2012 May-Jun;3(3):124-9. **IF: 3.880**
180. Sfikas A, Batsi C, Tselikou E, Vartholomatos G, Monokrousos N, Pappas P, Christoforidis S, Tzavaras T, Kanavaros P, **Gorgoulis VG**, Marcu KB, Kolettas E. *The canonical NF- κ B pathway differentially protects normal and human tumor cells from ROS-induced DNA damage*. **Cell Signal**. 2012 Nov;24(11):2007-23. **IF: 4.850**
181. Xanthoulis A, Kotsinas A, Tiniakos D, Fiska A, Tentis AA, Kyroudi A, Kittas C, **Gorgoulis V**. *The relationship between E2F family members and tumor growth in colorectal adenocarcinomas: A comparative immunohistochemical study of 100 cases*. **Appl Immunohistochem Mol Morphol**. 2014 Jul;22(6):471-7. **IF: 1.992**
182. Nowsheen S, Aziz K, Tran PT, **Gorgoulis VG**, Yang ES, Georgakilas AG. *Epigenetic inactivation of DNA repair in breast cancer*. **Cancer Lett**. 2012 May 23. **IF: 9.756**
183. Thanopoulou E, Kotzamanis G, Pateras IS, Ziras N, Papalambros A, Mariolis-Sapsakos T, Sigala F, Johnson E, Kotsinas A, Scorilas A, **Gorgoulis VG**. *The single nucleotide polymorphism g.1548A >G (K469E) of the ICAM-1 gene is associated with worse prognosis in non-small cell lung cancer*. **Tumour Biol**. 2012 Oct;33(5):1429-36. **IF: 2.47**
184. Giotakis E, Gomatos IP, Alevizos L, Manolopoulos L, Kataki A, Kandiloros D, **Gorgoulis VG**, Tsimaratou K, Konstantoulakis MM, Yiotakis I. *Apoptotic and proliferative status in HPV (+) and HPV (-) inverted papilloma patients. Correlation with local recurrence and clinicopathological variables*. **Pathol Res Pract**. 2012 Jun 15;208(6):338-43. **IF: 3.309**
185. Pateras IS, Evangelou K, Tsimaratou K, Liontos M, Sakellariou S, Barlogiannis T, Karakitsos P, Papalois A, Kotsinas A, **Gorgoulis VG**. *Detection of herpes simplex virus-1 and -2 in cardiac myxomas*. **J Biomed Biotechnol**. 2012;2012:823949. **IF: 0.680**
186. Dijkstra JR, Opdam FJ, Boonyaratanakornkit J, Schönbrunner ER, Shahbazian M, Edsjö A, Hoefler G, Jung A, Kotsinas A, **Gorgoulis VG**, López-Ríos F, de Stricker K, Rouleau E, Biesmans B, van Krieken JH. *Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis*. **J Mol Diagn**. 2012 May-Jun;14(3):187-91. **IF: 5.341**
187. Georgakopoulou EA, Troupis TG, Troupis G, **Gorgoulis VG**. *Update of the cancer-associated molecular mechanisms in oral lichen planus, a disease with possible premalignant nature*. **J BUON**. 2011 Oct-Dec;16(4):613-6. **IF: 2.533**
188. Liontos M, Pateras IS, Evangelou K, **Gorgoulis VG**. *The tumor suppressor gene ARF as a sensor of oxidative stress*. **Curr Mol Med**. 2012 Jul 1;12(6):704-15. **IF: 2.616**

189. Aziz K, Newsheer S, Pantelias G, Iliakis G, **Gorgoulis VG**, Georgakilas AG. *Targeting DNA damage and repair: embracing the pharmacological era for successful cancer therapy.* **Pharmacol Ther.** 2012 Mar;133(3):334-50. **IF: 13.400**
190. Kotsinas A, Aggarwal V, Tan EJ, Levy B, **Gorgoulis VG**. *PIG3: a novel link between oxidative stress and DNA damage response in cancer.* **Cancer Lett.** 2012 Dec 31;327(1-2):97-102. **IF: 9.756**
191. Sideridou M, Zakopoulou R, Evangelou K, Lontos M, Kotsinas A, Rampakakis E, Gagos S, Kahata K, Grabusic K, Gkouskou K, Trougakos IP, Kolettas E, Georgakilas AG, Volarevic S, Eliopoulos AG, Zannis-Hadjopoulos M, Moustakas A, **Gorgoulis VG**. *Cdc6 expression represses E-cadherin transcription and activates adjacent replication origins.* **J Cell Biol.** 2011 Dec 26;195(7):1123-40. **IF: 8.077**
192. Cheung W, Kotzamanis G, Abdulrazzak H, Goussard S, Kaname T, Kotsinas A, **Gorgoulis VG**, Grillot-Courvalin C, Huxley C. *Bacterial delivery of large intact genomic-DNA-containing BACs into mammalian cells.* **Bioeng Bugs.** 2012 Mar-Apr;3(2):86-92. **IF: 1.800**
193. Troupis TG, Chatzikokolis S, Michalinos A, Sarakinos A, Kotsopoulos P, Patsea H, Kotsinas A, Evangelou K, **Gorgoulis VG**. *GIST mimicking an hyperplastic polyp of descending colon.* **Ann Ital Chir.** 2011 Mar-Apr;82(2):141-6. **IF: 0.730**
194. Bamias G, Evangelou K, Vergou T, Tsimaratou K, Kaltsa G, Antoniou C, Kotsinas A, Kim S, **Gorgoulis V**, Stratigos AJ, Sfikakis PP. *Upregulation and nuclear localization of TNF-like cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions.* **Exp Dermatol.** 2011 Sep;20(9):725-31. **IF: 4.511**
195. Bellon E, Ligtenberg MJ, Tejpar S, Cox K, de Hertogh G, de Stricker K, Edsjö A, **Gorgoulis V**, Höfler G, Jung A, Kotsinas A, Laurent-Puig P, López-Ríos F, Hansen TP, Rouleau E, Vandenberghe P, van Krieken JJ, Dequeker E. *External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.* **Oncologist** 2011;16(4):467-78. **IF: 5.837**
196. Di Micco R, Sulli G, Dobrova M, Lontos M, Botrugno OA, Gargiulo G, dal Zuffo R, Matti V, d'Ario G, Montani E, Mercurio C, Hahn WC, **Gorgoulis V**, Minucci S, d'Adda di Fagagna F. *Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer.* **Nat Cell Biol.** 2011 Mar;13(3):292-302. **IF: 28.213**
197. Schramek D, Kotsinas A, Meixner A, Wada T, Elling U, Pospisilik JA, Neely GG, Zwick RH, Sigl V, Forni G, Serrano M, **Gorgoulis VG**, Penninger JM. *The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression.* **Nat Genet.** 2011 Mar;43(3):212-9. **IF: 41.307**
198. Tyrizis SI, Zachariades M, Evangelou K, **Gorgoulis VG**, Kyroudi-Voulgari A, Pavlakis K, Troupis TG, Constantinides CA. *Effects of prolonged warm and cold ischemia in a solitary kidney animal model after partial nephrectomy: an ultrastructural investigation.* **Ultrastruct Pathol.** 2011 Apr;35(2):60-5. **IF: 1.385**
199. Damalas A, Velimezi G, Kalaitzakis A, Lontos M, Papavassiliou AG, **Gorgoulis V**, Angelidis C. *Loss of p14(ARF) confers resistance to heat shock- and oxidative stress-mediated cell death by upregulating β -catenin.* **Int J Cancer** 2011 Apr 15;128(8):1989-95. **IF: 7.316**
200. Lontos M, Velimezi G, Pateras IS, Angelopoulou R, Papavassiliou AG, Bartek J, **Gorgoulis VG**. *The roles of p27(Kip1) and DNA damage signaling in the chemotherapy-induced delayed cell cycle checkpoint.* **J Cell Mol Med.** 2010 Sep;14(9):2264-7. **IF: 5.295**

201. Sigala F, Kotsinas A, Savari P, Filis K, Markantonis S, Iliodromitis EK, **Gorgoulis VG**, Andreadou I. *Oxidized LDL in human carotid plaques is related to symptomatic carotid disease and lesion instability*. **J Vasc Surg**. 2010 Sep;52(3):704-13. **IF: 4.860**
202. Kotsinas A, Pateras IS, Galanos PS, Karamouzis MV, Sfrikakis PP, **Gorgoulis VG**. *Why is p53-inducible gene 3 rarely affected in cancer?* **Oncogene** 2010 Sep 16;29(37):5220. **IF: 8.756**
203. Logotheti S, Michalopoulos I, Sideridou M, Daskalos A, Kossida S, Spandidos DA, Field JK, Vojtesek B, Liloglou T, **Gorgoulis V**, Zoumpourlis V. *Sp1 binds to the external promoter of the p73 gene and induces the expression of TAp73gamma in lung cancer*. **FEBS J** 2010 Jul;277(14):3014-27. **IF: 5.622**
204. **Gorgoulis VG**, Halazonetis TD. *Oncogene-induced senescence: the bright and dark side of the response*. **Curr Opin Cell Biol**. 2010 Dec;22(6):816-27. **IF: 8.386**
205. Sigala F, Savvari P, Lontos M, Sigalas P, Pateras IS, Papalampros A, Basdra EK, Kolettas E, Kotsinas A, Papavassiliou AG, **Gorgoulis VG**. *Increased expression of bFGF is associated with carotid atherosclerotic plaques instability engaging the NF-kappaB pathway*. **J Cell Mol Med**. 2010 Sep;14(9):2273-80. **IF: 5.295**
206. Chrysovergis A, **Gorgoulis VG**, Giotakis I, Tsiambas E, Karameris A, Kittas C, Kyroudi A. *Simultaneous over activation of EGFR, telomerase (h TERT), and cyclin D1 correlates with advanced disease in larynx squamous cell carcinoma: a tissue microarray analysis*. **Med Oncol**. 2011 Sep;28(3):871-7. **IF: 3.738**
207. Negrini S, **Gorgoulis VG**, Halazonetis TD. *Genomic instability-an evolving hallmark of cancer*. **Nat Rev Mol Cell Biol**. 2010 Mar;11(3):220-8. **IF: 113.915**
208. Pateras IS, Apostolopoulou K, Niforou K, Kotsinas A, **Gorgoulis VG**. *p57KIP2: "Kip"ing the cell under control*. **Mol Cancer Res**. 2009 Dec;7(12):1902-19. **IF: 6.333**
209. Papachristou DJ, Papachroni KK, Papavassiliou GA, Pirttiniemi P, **Gorgoulis VG**, Piperi C, Basdra EK. *Functional alterations in mechanical loading of condylar cartilage induces changes in the bony subcondylar region*. **Arch Oral Biol**. 2009 Nov;54(11):1035-45. **IF: 2.640**
210. Lontos M, Niforou K, Velimezi G, Vougas K, Evangelou K, Apostolopoulou K, Vrtel R, Damalas A, Kontovazenitis P, Kotsinas A, Zoumpourlis V, Tsangaris GT, Kittas C, Ginsberg D, Halazonetis TD, Bartek J, **Gorgoulis VG**. *Modulation of the E2F1-driven cancer cell fate by the DNA damage response machinery and potential novel E2F1 targets in osteosarcomas*. **Am J Pathol**. 2009 Jul;175(1):376-91. **IF: 5.770**
211. Batsi C, Markopoulou S, Vartholomatos G, Georgiou I, Kanavaros P, **Gorgoulis VG**, Marcu KB, Kolettas E. *Chronic NF-kappaB activation delays RasV12-induced premature senescence of human fibroblasts by suppressing the DNA damage checkpoint response*. **Mech Ageing Dev**. 2009 Jul;130(7):409-19. **IF: 5.498**
212. Woodcock SA, Rooney C, Lontos M, Connolly Y, Zoumpourlis V, Whetton AD, **Gorgoulis VG**, Malliri A. *SRC-induced disassembly of adherens junctions requires localized phosphorylation and degradation of the rac activator tiam1*. **Mol Cell**. 2009 Mar 13;33(5):639-53. **IF: 19.328**
213. Papadakis V, Karakasis D, Sfrikakis PP, Baltadakis I, Apostolidis J, Evangelou K, **Gorgoulis VG**, Harhalakis N. *Is imatinib mesylate a promising drug in scleroderma due to extensive chronic graft-versus-host disease?* **Leuk Lymphoma**. 2009 Mar;50(3):471-4. **IF: 2.996**
214. Trougakos IP, Lourda M, Antonelou MH, Kletsas D, **Gorgoulis VG**, Papassideri IS, Zou Y, Margaritis LH, Boothman DA, Gonos ES. *Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing*

- the cytosolic Ku70-Bax protein complex. Clin Cancer Res.* 2009 Jan 1;15(1):48-59. **IF: 13.801**
215. Koutsami M, Velimezi G, Kotsinas A, Evangelou K, Papavassiliou AG, Kittas C, **Gorgoulis VG**. *Is exclusive Skp2 targeting always beneficial in cancer therapy? Blood* 2008 Dec 1;112(12):4777-9. **IF: 25.476**
216. Daskalos A, Nikolaidis G, Xinarianos G, Savvari P, Cassidy A, Zakopoulou R, Kotsinas A, **Gorgoulis V**, Field JK, Liloglou T. *Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int J Cancer* 2009 Jan 1;124(1):81-7. **IF: 7.316**
217. Kotzamanis G, Abdulrazzak H, Gifford-Garner J, Haussecker PL, Cheung W, Grillot-Courvalin C, Harris A, Kittas C, Kotsinas A, **Gorgoulis VG**, Huxley C. *CFTR expression from a BAC carrying the complete human gene and associated regulatory elements. J Cell Mol Med.* 2009 Sep;13(9A):2938-48. **IF: 5.295**
218. Gazouli M, Koundourakis A, Ikonomopoulos J, Gialafos EJ, Papaconstantinou I, Nasioulas G, Lukas JC, **Gorgoulis VG**. *The functional polymorphisms of NRAMP1 gene in Greeks with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis.* 2007 Sep;24(2):153-4. **IF: 1.803**
219. Niforou KM, Anagnostopoulos AK, Vougas K, Kittas C, **Gorgoulis VG**, Tsangaris GT. *The proteome profile of the human osteosarcoma U2OS cell line. Cancer Genomics Proteomics.* 2008 Jan-Feb;5(1):63-78. **IF: 3.395**
220. Vlahopoulos SA, Logotheti S, Mikas D, Giarika A, **Gorgoulis V**, Zoumpourlis V. *The role of ATF-2 in oncogenesis. Bioessays.* 2008 Apr;30(4):314-27. **IF: 4.653**
221. Sfrikakis PP, **Gorgoulis VG**, Katsiari CG, Evangelou K, Kostopoulos C, Black CM. *Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford).* 2008 May;47(5):735-7. **IF: 7.046**
222. Halazonetis TD, **Gorgoulis VG**, Bartek J. *An oncogene-induced DNA damage model for cancer development. Science.* 2008 Mar 7;319(5868):1352-5. **IF: 63.714**
223. Tsantoulis PK, Kotsinas A, Sfrikakis PP, Evangelou K, Sideridou M, Levy B, Mo L, Kittas C, Wu XR, Papavassiliou AG, **Gorgoulis VG**. *Oncogene-induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study. Oncogene.* 2008 May 22;27(23):3256-64. **IF: 8.756**
224. Kotsinas A, Evangelou K, Sideridou M, Kotzamanis G, Constantinides C, Zavras AI, Douglass CW, Papavassiliou AG, **Gorgoulis VG**. *The 3' UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer. Cancer Lett.* 2008 Feb 8;259(2):177-85. **IF: 9.756**
225. Lontos M, Koutsami M, Sideridou M, Evangelou K, Kletsas D, Levy B, Kotsinas A, Nahum O, Zoumpourlis V, Kouloukoussa M, Lygerou Z, Taraviras S, Kittas C, Bartkova J, Papavassiliou AG, Bartek J, Halazonetis TD, **Gorgoulis VG**. *Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. Cancer Res.* 2007a Nov 15;67(22):10899-909. **IF: 13.312**
226. Evangelou K, Kotsinas A, Mariolis-Sapsakos T, Giannopoulos A, Tsantoulis PK, Constantinides C, Troupis TG, Salmas M, Kyroudis A, Kittas C, **Gorgoulis VG**. *E2F-1 overexpression correlates with decreased proliferation and better prognosis in adenocarcinomas of Barrett oesophagus. J Clin Pathol.* 2008 May;61(5):601-5. **IF: 4.463**
227. Apostolopoulou K, Pateras IS, Evangelou K, Tsantoulis PK, Lontos M, Kittas C, Tiniakos DG, Kotsinas A, Cordon-Cardo C, **Gorgoulis VG**. *Gene amplification is a relatively frequent event leading to ZBTB7A (Pokemon) overexpression in non-small cell lung cancer. J Pathol.* 2007 Nov;213(3):294-302. **IF: 9.883**

228. Fotiadis C, Adamis S, Misiakos EP, Genetzakis M, Antonakis PT, Tsekouras DK, **Gorgoulis VG**, Zografos GC, Papalois A, Fotinou M, Perrea D. *The prophylactic effect of L-arginine in acute ischaemic colitis in a rat model of ischaemia/reperfusion injury*. **Acta Chir Belg**. 2007 Mar-Apr;107(2):192-200. **IF: 0.990**
229. Weisz L, Damalas A, Lontos M, Karakaidos P, Fontemaggi G, Maor-Aloni R, Kalis M, Levrero M, Strano S, **Gorgoulis VG**, Rotter V, Blandino G, Oren M. *Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells*. **Cancer Res**. 2007b Mar 15;67(6):2396-401. **IF: 13.312**
230. Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G, **Gorgoulis VG**. *Advances in the biology of oral cancer*. **Oral Oncol**. 2007 Jul;43(6):523-34. **IF: 5.972**
231. Andreadou I, Sigala F, Iliodromitis EK, Papaefthimiou M, Sigalas C, Aligiannis N, Savvari P, **Gorgoulis V**, Papalabros E, Kremastinos DT. *Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress*. **J Mol Cell Cardiol**. 2007 Mar;42(3):549-58. **IF: 5.763**
232. Ikonomopoulos J, Gazouli M, Dontas I, Sechi L, Lukas JC, Balaskas C, **Gorgoulis V**, Kittas C. *The infectivity of sarcoid clinical material and its bacterial content inoculated in CBA mice*. **In Vivo**. 2006 Nov-Dec;20(6B):807-13. **IF: 2.406**
233. Tsimaratou K, Kletsas D, Kastrinakis NG, Tsantoulis PK, Evangelou K, Sideridou M, Lontos M, Poulias I, Venere M, Salmas M, Kittas C, Halazonetis TD, **Gorgoulis VG**. *Evaluation of claspin as a proliferation marker in human cancer and normal tissues*. **J Pathol**. 2007 Feb;211(3):331-9. **IF: 9.883**
234. Bartkova J, Rezaei N, Lontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC, Takaoka M, Nakagawa H, Tort F, Fugger K, Johansson F, Sehested M, Andersen CL, Dyrskjot L, Ørntoft T, Lukas J, Kittas C, Helleday T, Halazonetis TD, Bartek J, **Gorgoulis VG**. *Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints*. **Nature**. 2006 Nov 30;444(7119):633-7. **IF: 69.504**
235. Kouerinis IA, Manopoulos CG, Zografos GC, Apostolakis EI, Tsilimingas NB, Argiriou ME, **Gorgoulis VG**, Dedeilias PG, Tsoukas A, Bolos K, Tsangaris SG. *Retrograde cardioplegia in CABG: is it really useful? The microcirculation and a capillary unit model*. **Med Sci Monit**. 2006 Nov;12(11):RA265-8. **IF: 3.386**
236. Pateras IS, Apostolopoulou K, Koutsami M, Evangelou K, Tsantoulis P, Liloglou T, Nikolaidis G, Sigala F, Kittas C, Field JK, Kotsinas A, **Gorgoulis VG**. *Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer*. **Int J Cancer** 2006 Dec 1;119(11):2546-56. **IF: 7.316**
237. Gazouli M, Koundourakis A, Ikonomopoulos J, Gialafos EJ, Rapti A, **Gorgoulis VG**, Kittas C. *CARD15/NOD2, CD14, and toll-like receptor 4 gene polymorphisms in Greek patients with sarcoidosis*. **Sarcoidosis Vasc Diffuse Lung Dis**. 2006 Mar;23(1):23-9. **IF: 1.803**
238. Ziori H, Kyriakidis M, Zioris H, **Gorgoulis V**, Kostomitsopoulos N, Kittas Ch, Karayannakos P. *The effects of enalapril on p53 expression in left ventricular cardiomyocytes after aortic stenosis*. **In Vivo**. 2006 Jul-Aug;20(4):459-65. **IF: 2.406**
239. Sigala F, Georgopoulos S, Papalambros E, Chasiotis D, Vourliotakis G, Niforou A, Kotsinas A, Kavantzias N, Patsouris E, **Gorgoulis VG**, Bastounis E. *Heregulin, cysteine rich-61 and matrix metalloproteinase 9 expression in human carotid atherosclerotic plaques: relationship with clinical data*. **Eur J Vasc Endovasc Surg**. 2006 Sep;32(3):238-45. **IF: 6.427**

240. Tsoli E, Tsantoulis PK, Papalambros A, Perunovic B, England D, Rawlands DA, Reynolds GM, Vlachodimitropoulos D, Morgan SL, Spiliopoulou CA, Athanasiou T, **Gorgoulis VG**. *Simultaneous evaluation of maspin and CXCR4 in patients with breast cancer*. **J Clin Pathol**. 2007 Mar;60(3):261-6. **IF: 4.463**
241. Koutsami MK, Tsantoulis PK, Kouloukoussa M, Apostolopoulou K, Pateras IS, Spartinou Z, Drougou A, Evangelou K, Kittas C, Bartkova J, Bartek J, **Gorgoulis VG**. *Centrosome abnormalities are frequently observed in non-small-cell lung cancer and are associated with aneuploidy and cyclin E overexpression*. **J Pathol**. 2006 Aug;209(4):512-21. **IF: 9.883**
242. Kouerinis IA, Zografos GC, Apostolakis EI, Menenakos EI, Anthopoulos P, Fotiadis CI, **Gorgoulis VG**, Argiriou ME, Bellenis IP. *Spontaneous rupture of the colon sigmoid following spontaneous recurrent pneumothorax in a patient with Marfan syndrome*. **Med Sci Monit**. 2006 Mar;12(3):CS21-3. **IF: 3.386**
243. Tsantoulis PK, **Gorgoulis VG**. *Involvement of E2F transcription factor family in cancer*. **Eur J Cancer** 2005 Nov;41(16):2403-14. **IF: 10.002**
244. Fotiadis C, Leventis I, Adamis S, **Gorgoulis V**, Domeyer P, Zografos G, Sechas M, Skalkeas G. *The use of isobutylcyanoacrylate as a tissue adhesive in abdominal surgery*. **Acta Chir Belg**. 2005 Aug;105(4):392-6. **IF: 0.990**
245. Gazouli M, Ikonopoulou J, Koundourakis A, Bartos M, Pavlik I, Overduin P, Kremer K, **Gorgoulis V**, Kittas C. *Characterization of Mycobacterium tuberculosis complex isolates from Greek patients with sarcoidosis by Spoligotyping*. **J Clin Microbiol**. 2005 Sep;43(9):4858-61. **IF: 11.677**
246. Livingstone M, Ruan H, Weiner J, Clauser KR, Strack P, Jin S, Williams A, Greulich H, Gardner J, Venere M, Mochan TA, DiTullio RA Jr, Moravcevic K, **Gorgoulis VG**, Burkhardt A, Halazonetis TD. *Valosin-containing protein phosphorylation at Ser784 in response to DNA damage*. **Cancer Res**. 2005 Sep 1;65(17):7533-40. **IF: 13.312**
247. Melissourgos ND, Kastrinakis NG, Skolarikos A, Pappa M, Vassilakis G, **Gorgoulis VG**, Salla C. *Cytokeratin-20 immunocytology in voided urine exhibits greater sensitivity and reliability than standard cytology in the diagnosis of transitional cell carcinoma of the bladder*. **Urology**. 2005 Sep;66(3):536-41. **IF: 2.633**
248. **Gorgoulis VG**, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, DiTullio RA Jr, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD. *Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions*. **Nature** 2005 Apr 14;434(7035):907-13. **IF: 69.504**
249. Sigala F, Papalambros E, Kotsinas A, Andreadou I, Sigalas P, Kremastinos D, Bastounis E, **Gorgoulis VG**. *Relationship between iNOS expression and aortic cell proliferation and apoptosis in an elastase-induced model of aorta aneurysm and the effect of 1400 W administration*. **Surgery**. 2005 Apr;137(4):447-56. **IF: 4.348**
250. **Gorgoulis VG**, Pratsinis H, Zacharatos P, Demoliou C, Sigala F, Asimacopoulos PJ, Papavassiliou AG, Kletsas D. *p53-dependent ICAM-1 overexpression in senescent human cells identified in atherosclerotic lesions*. **Lab Invest**. 2005 Apr;85(4):502-11. **IF: 5.502**
251. Gazouli M, Mantzaris G, Kotsinas A, Zacharatos P, Papalambros E, Archimandritis A, Ikonopoulou J, **Gorgoulis VG**. *Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population*. **World J Gastroenterol**. 2005 Feb 7;11(5):681-5. **IF: 5.374**
252. Mitropoulos D, Deliconstantinos G, Adamakis I, Zervas A, Karakaidos P, **Gorgoulis VG**. *Changes in end products of nitric oxide in urine and induction of*

- nitric oxide synthase expression in urinary bladder during intravesical instillations of IFN-alpha2b.* **J Interferon Cytokine Res.** 2004 Oct;24(10):621-6. **IF: 3.657**
253. Papassava P, **Gorgoulis VG**, Papaevangelidou D, Vlahopoulos S, van Dam H, Zoumpourlis V. *Overexpression of activating transcription factor-2 is required for tumor growth and progression in mouse skin tumors.* **Cancer Res.** 2004 Dec 1;64(23):8573-84. **IF: 13.312**
254. Huyen Y, Zgheib O, Ditullio RA Jr, **Gorgoulis VG**, Zacharatos P, Petty TJ, Sheston EA, Mellert HS, Stavridi ES, Halazonetis TD. *Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks.* **Nature** 2004 Nov 18;432(7015):406-11. **IF: 69.504**
255. Bramis J, Zacharatos P, Papaconstantinou I, Kotsinas A, Sigala F, Korkolis DP, Nikiteas N, Pazaiti A, Kittas C, Bastounis E, **Gorgoulis VG**. *E2F-1 transcription factor immunoexpression is inversely associated with tumor growth in colon adenocarcinomas.* **Anticancer Res.** 2004 Sep-Oct;24(5A):3041-7. **IF: 2.435**
256. **Gorgoulis VG**, Liloglou T, Sigala F, Korkolis D, Yannoukakos D, Papalambros E, Asimacopoulos PJ, Papavassiliou AG, Kotsinas A. *Absence of association with cancer risk and low frequency of alterations at a p53 responsive PIG3 gene polymorphism in breast and lung carcinomas.* **Mutat Res.** 2004 Nov 22;556(1-2):143-50. **IF: 3.151**
257. Gazouli M, Zacharatos P, Mantzaris GJ, Barbatis C, Ikonopoulou I, Archimandritis AJ, Lukas JC, Papalambros E, **Gorgoulis V**. *Association of NOD2/CARD15 variants with Crohn's disease in a Greek population.* **Eur J Gastroenterol Hepatol.** 2004 Nov;16(11):1177-82. **IF: 2.586**
258. Karakaidos P, Taraviras S, Vassiliou LV, Zacharatos P, Kastrinakis NG, Kougiou D, Kouloukoussa M, Nishitani H, Papavassiliou AG, Lygerou Z, **Gorgoulis VG**. *Overexpression of the replication licensing regulators hCdt1 and hCdc6 characterizes a subset of non-small-cell lung carcinomas: synergistic effect with mutant p53 on tumor growth and chromosomal instability-evidence of E2F-1 transcriptional control over hCdt1.* **Am J Pathol** 2004 Oct;165(4):1351-65. **IF: 5.770**
259. Pilichos CJ, Kouerinis IA, Zografos GC, Korkolis DP, Preza AA, Gazouli M, Menenakos EI, Loutsidis AE, Zagouri F, **Gorgoulis VG**, Fotiadis CI. *The effect of nitric oxide synthases inhibitors on inflammatory bowel disease in a rat model.* **In Vivo.** 2004 Jul-Aug;18(4):513-6. **IF: 2.406**
260. Korkolis DP, Tsoi E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, **Gorgoulis VG**. *Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.* **Anticancer Res.** 2004 May-Jun;24(3b):2061-8. **IF: 2.435**
261. Kletsas D, Pratsinis H, Mariatos G, Zacharatos P, **Gorgoulis VG**. *The proinflammatory phenotype of senescent cells: the p53-mediated ICAM-1 expression.* **Ann N Y Acad Sci.** 2004 Jun;1019:330-2. **IF: 5.167**
262. Evangelou K, Bramis J, Peros I, Zacharatos P, Dasiou-Plakida D, Kalogeropoulos N, Asimacopoulos PJ, Kittas C, Marinos E, **Gorgoulis VG**. *Electron microscopy evidence that cytoplasmic localization of the p16(INK4A) "nuclear" cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and not an artifact. A study in non-small cell lung carcinomas.* **Biotech Histochem.** 2004 Feb;79(1):5-10. **IF: 1.718**
263. Zacharatos P, Kotsinas A, Evangelou K, Karakaidos P, Vassiliou LV, Rezaei N, Kyroudi A, Kittas C, Patsouris E, Papavassiliou AG, **Gorgoulis VG**. *Distinct expression patterns of the transcription factor E2F-1 in relation to tumour growth parameters in common human carcinomas.* **J Pathol.** 2004 Jul;203(3):744-53. **IF: 9.883**

264. Kouerinis IA, Zografos G, Tarassi KE, Athanasiades TH, Lontos M, **Gorgoulis VG**, Korkolis D, Konstandoulakis MM, Fotiadis CI, Androulakis G, Papasteriades CA. *Human leukocyte antigens as genetic markers in Greek patients with sporadic pancreatic cancer*. **Pancreas**. 2004 Jul;29(1):41-4. **IF: 3.243**
265. Leventis I, Andreadou I, Papalois A, Sfiniadakis I, **Gorgoulis VG**, Korkolis DP, Hadjipavlou-Litina D, Kourounakis PN, Fotiadis C. *A novel antioxidant non-steroidal anti-inflammatory agent protects rat liver against ischemia-reperfusion injury*. **In Vivo**. 2004 Mar-Apr;18(2):161-9. **IF: 2.406**
266. Ikonopopoulos J, Gazouli M, Pavlik I, Bartos M, Zacharatos P, Xylouri E, Papalambros E, **Gorgoulis V**. *Comparative evaluation of PCR assays for the robust molecular detection of Mycobacterium avium subsp. paratuberculosis*. **J Microbiol Methods**. 2004 Mar;56(3):315-21. **IF: 2.622**
267. Gazouli M, Zacharatos P, **Gorgoulis V**, Mantzaris G, Papalambros E, Ikonopopoulos J. *The C3435T MDR1 gene polymorphism is not associated with susceptibility for ulcerative colitis in Greek population*. **Gastroenterology** 2004 Jan;126(1):367-9. **IF: 33.883**
268. Athanasiou T, Aziz O, Skapinakis P, Perunovic B, Hart J, Crossman MC, **Gorgoulis V**, Glenville B, Casula R. *Leg wound infection after coronary artery bypass grafting: a meta-analysis comparing minimally invasive versus conventional vein harvesting*. **Ann Thorac Surg**. 2003 Dec;76(6):2141-6. **IF: 2.535**
269. Sougioultzis S, Foukas PG, Tzivras M, Kourteas D, **Gorgoulis VG**, Davaris P, Archimandritis AJ. *Alterations in the proliferating compartment of gastric mucosa during Helicobacter pylori infection: the putative role of epithelial cells expressing p27(kip1)*. **Mod Pathol**. 2003 Nov;16(11):1076-85. **IF: 8.209**
270. Mariatos G, Bothos J, Zacharatos P, Summers MK, Scolnick DM, Kittas C, Halazonetis TD, **Gorgoulis VG**. *Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer*. **Cancer Res**. 2003 Nov 1;63(21):7185-9. **IF: 13.312**
271. Athanasiou A, Perunovic B, Quilty RD, **Gorgoulis VG**, Kittas C, Love S. *Expression of mos in ependymal gliomas*. **Am J Clin Pathol**. 2003 Nov;120(5):699-705. **IF: 5.400**
272. Andreadou I, Poussios D, Papalois A, Gavalakis N, Aroni K, Gazouli M, **Gorgoulis VG**, Fotiadis C. *Effect of U-74389G (21-lazaroid) on intestinal recovery after acute mesenteric ischemia and reperfusion in rats*. **In Vivo**. 2003 Sep-Oct;17(5):463-8. **IF: 2.406**
273. Giannopoulos A, Adamakis I, Evangelou K, Giannopoulou M, Zacharatos P, Zsantoulis P, Perunovic B, Athanasiou A, Retalis G, Constandinidis C, **Gorgoulis VG**. *Interferon- α 2b reduces neo-microvascular density in the 'normal' urothelium adjacent to the tumor after transurethral resection of superficial bladder carcinoma*. **Onkologie**. 2003 Apr;26(2):147-52. **IF: 1.522**
274. Puiu L, Petrakou E, Apostolidou A, Athanassiadou A, Psiouri L, Papachatzopoulou A, **Gorgoulis VG**, Kotsinas A, Tzoracoeleftherakis E, Maniatis GM, Voutsinas G. *Lack of Fas (APO-1/CD95) gene structural alterations or transcript variant ratio changes in breast cancer*. **Cancer Lett**. 2003 May 8;194(1):91-7. **IF: 9.756**
275. Ikonopopoulos J, Kokotas S, Gazouli M, Zavras A, Stoitsiou M, **Gorgoulis VG**. *Molecular diagnosis of leishmaniosis in dogs. Comparative application of traditional diagnostic methods and the proposed assay on clinical samples*. **Vet Parasitol**. 2003 Apr 18;113(2):99-113. **2.821**

276. **Gorgoulis VG**, Zacharatos P, Kotsinas A, Kletsas D, Mariatos G, Zoumpourlis V, Ryan KM, Kittas C, Papavassiliou AG. *p53 activates ICAM-1 (CD54) expression in an NF-kappaB-independent manner*. **EMBO J**. 2003 Apr 1;22(7):1567-78. **IF: 14.012**
277. Gazouli M, Kokotas S, Zoumpourlis V, Zacharatos P, Mariatos G, Kletsas D, Perunovic B, Athanasiou A, Kittas C, **Gorgoulis V**. *The complement inhibitor CD59 and the lymphocyte function-associated antigen-3 (LFA-3, CD58) genes possess functional binding sites for the p53 tumor suppressor protein*. **Anticancer Res**. 2002 Nov-Dec;22(6C):4237-41. **IF: 2.435**
278. Katsanakis KD, **Gorgoulis V**, Papavassiliou AG, Zoumpourlis VK. *The progression in the mouse skin carcinogenesis model correlates with ERK1/2 signaling*. **Mol Med**. 2002 Oct;8(10):624-37. **IF: 6.376**
279. Koutsami MK, Doussis-Anagnostopoulou I, Papavassiliou AG, **Gorgoulis VG**. *Genetic and molecular coordinates of neuroendocrine lung tumors, with emphasis on small-cell lung carcinomas*. **Mol Med**. 2002 Aug;8(8):419-36. **IF: 6.376**
280. Kotsinas A, Evangelou K, Zacharatos P, Kittas C, **Gorgoulis VG**. *Proliferation, but not apoptosis, is associated with distinct beta-catenin expression patterns in non-small-cell lung carcinomas: relationship with adenomatous polyposis coli and G(1)-to S-phase cell-cycle regulators*. **Am J Pathol**. 2002 Nov;161(5):1619-34. **IF: 5.770**
281. **Gorgoulis VG**, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D, Asimacopoulos PJ, Agnantis N, Kittas C, Papavassiliou AG. *Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas*. **J Pathol**. 2002 Oct;198(2):142-56. **IF: 9.883**
282. Doussis-Anagnostopoulou IA, Talks KL, Turley H, Debnam P, Tan DC, Mariatos G, **Gorgoulis V**, Kittas C, Gatter KC. *Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed-Sternberg cells in Hodgkin's disease*. **J Pathol**. 2002 Aug;197(5):677-83. **IF: 9.883**
283. Tsoi E, Zacharatos P, Dasiou-Plakida D, Peros J, Evangelou K, Zavras AI, Yannoukakos D, Konstantopoulou I, Asimacopoulos PJ, Kittas C, **Gorgoulis VG**. *Growth index is independent of microvessel density in non-small-cell lung carcinomas*. **Hum Pathol**. 2002 Aug;33(8):812-8. **IF: 3.526**
284. Perunovic B, Athanasiou A, Quilty RD, **Gorgoulis VG**, Kittas C, Love S. *Expression of mos in astrocytic tumors and its potential role in neoplastic progression*. **Hum Pathol**. 2002 Jul;33(7):703-7. **IF: 3.526**
285. Gazouli M, Ikonomopoulos J, Trigidou R, Foteinou M, Kittas C, **Gorgoulis V**. *Assessment of mycobacterial, propionibacterial, and human herpesvirus 8 DNA in tissues of greek patients with sarcoidosis*. **J Clin Microbiol**. 2002 Aug;40(8):3060-3. **IF: 11.677**
286. Evangelou K, Balaskas C, Marinos E, Dosios T, Kittas C, **Gorgoulis VG**. *Immunohistochemical localization of c-mos at the light and electron microscope level in non-small cell lung carcinomas*. **Biotech Histochem**. 2002 Mar;77(2):85-91. **IF: 1.718**
287. Koutsami MK, **Gorgoulis VG**, Kastrinakis NG, Asimacopoulos PJ, Kittas C. *Prognostic factors in non-small cell lung carcinoma*. **Anticancer Res**. 2002 Jan-Feb;22(1A):347-74. **IF: 2.435**
288. Kouvaraki M, **Gorgoulis VG**, Rassidakis GZ, Liodis P, Markopoulos C, Gogas J, Kittas C. *High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas: relation to E-cadherin alterations, proliferative activity, and ploidy of the tumors*. **Cancer**. 2002 May 1;94(9):2454-65. **IF: 6.921**

289. Karamouzis MV, **Gorgoulis VG**, Papavassiliou AG. *Transcription factors and neoplasia: vistas in novel drug design*. **Clin Cancer Res**. 2002 May;8(5):949-61. **IF: 13.801**
290. Sfikakis PP, **Gorgoulis VG**, Kapsogeorgou EK, Tsoli E, Manoussakis MN. *Absence of p53 gene mutations in skin fibroblasts derived from patients with systemic sclerosis*. **Eur J Clin Invest**. 2002 Feb;32(2):139-40. **IF: 5.722**
291. Spanakis NE, Garinis GA, Alexopoulos EC, Patrinos GP, Menounos PG, Sklavounou A, Manolis EN, **Gorgoulis VG**, Valis D. *Cytokine serum levels in patients with chronic HCV infection*. **J Clin Lab Anal**. 2002;16(1):40-6. **IF: 3.124**
292. Sampaziotis F, Kokotas S, **Gorgoulis VG**. *P53 possibly upregulates the expression of CD58 (LFA-3) and CD59 (MIRL)*. **Med Hypotheses**. 2002 Feb;58(2):136-40. **IF: 4.411**
293. Zacharatos P, Kotsinas A, Tsantoulis P, Evangelou K, Kletsas D, Asimacopoulos PJ, Doussis-Anagnostopoulou I, Pezzella F, Gatter K, Papavassiliou AG, Kittas C, **Gorgoulis VG**. *Relationship of the K-ras/c-mos expression patterns with angiogenesis in non-small cell lung carcinomas*. **Mol Med**. 2001 Sep;7(9):590-7. **IF: 6.376**
294. Foukas PG, Tsilivakos V, Zacharatos P, Mariatos G, Moschos S, Syrianiou A, Asimacopoulos PJ, Bramis J, Fotiadis C, Kittas C, **Gorgoulis VG**. *Expression of HLA-DR is reduced in tumor infiltrating immune cells (TICs) and regional lymph nodes of non-small-cell lung carcinomas. A putative mechanism of tumor-induced immunosuppression?* **Anticancer Res**. 2001 Jul-Aug;21(4A):2609-15. **IF: 2.435**
295. Kanavaros P, Stefanaki K, Rontogianni D, Papalazarou D, Sgantzios M, Arvanitis D, Vamvouka C, **Gorgoulis V**, Siatitsas I, Agnantis NJ, Bai M. *Immunohistochemical expression of p53, p21/waf1, rb, p16, cyclin D1, p27, Ki67, cyclin A, cyclin B1, bcl2, bax and bak proteins and apoptotic index in normal thymus*. **Histol Histopathol**. 2001 Oct;16(4):1005-12. **IF: 2.130**
296. Korkolis D, Ardavanis A, Yotis J, Kyroudi A, **Gorgoulis V**, Kittas C. *HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D*. **Anticancer Res**. 2001 May-Jun;21(3C):2207-12. **IF: 2.435**
297. Tsoli E, **Gorgoulis VG**, Zacharatos P, Kotsinas A, Mariatos G, Kastrinakis NG, Kokotas S, Kanavaros P, Asimacopoulos P, Bramis J, Kletsas D, Papavassiliou AG, Kittas C. *Low levels of p27 in association with deregulated p53-pRb protein status enhance tumor proliferation and chromosomal instability in non-small cell lung carcinomas*. **Mol Med**. 2001 Jun;7(6):418-29. **IF: 6.376**
298. Mariatos G, **Gorgoulis VG**, Laskaris G, Kittas C. *Epithelioid haemangioma (angiolymphoid hyperplasia with eosinophilia) in the inner canthus*. **J Eur Acad Dermatol Venereol**. 2001 Jan;15(1):90-1. **IF: 9.228**
299. Kouvaraki M, **Gorgoulis VG**, Rassidakis GZ, Liodis P, Koutroumbi E, Markopoulos C, Gogas J, Kittas C. *Alterations of the 16q22.1 and 16q24.3 chromosomal loci in sporadic invasive breast carcinomas: correlation with proliferative activity, ploidy and hormonal status of the tumors*. **Anticancer Res**. 2001 Mar-Apr;21(2A):991-9. **IF: 2.435**
300. Kotsinas A, **Gorgoulis VG**, Zacharatos P, Mariatos G, Kokotas S, Liloglou T, Ikononopoulos J, Zoumpourlis V, Kyroudi A, Field JK, Asimacopoulos PJ, Kittas C. *Additional characterization of a hexanucleotide polymorphic site in the first intron of human H-ras gene: comparative study of its alterations in non-small cell lung carcinomas and sporadic invasive breast carcinomas*. **Cancer Genet Cytogenet**. 2001 Apr 15;126(2):147-54. **IF: 1.929**

301. Kanavaros P, Bai M, Stefanaki K, Poussias G, Rontogianni D, Zioga E, **Gorgoulis V**, Agnantis NJ. *Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas.* **Histol Histopathol.** 2001 Apr;16(2):377-86. **IF: 2.130**
302. Vassilakopoulos T, Troupis T, Sotiropoulou C, Zacharatos P, Katsaounou P, Parthenis D, Noussia O, Troupis G, Papiris S, Kittas C, Roussos C, Zakyntinos S, **Gorgoulis V**. *Diagnostic and prognostic significance of squamous cell carcinoma antigen in non-small cell lung cancer.* **Lung Cancer.** 2001 May;32(2):137-44. **IF: 6.081**
303. Kotsinas A, **Gorgoulis VG**, Zacharatos P, Liloglou T, Leonardou P, Bramis J, Troupis TG, Fotiadis C, Field JK, Kittas C. *A new rare allele at the CGG repeat polymorphism in the first intron of human c-H-ras gene.* **In Vivo.** 2001 Jan-Feb;15(1):105-8. **IF: 2.406**
304. **Gorgoulis VG**, Zacharatos P, Mariatos G, Liloglou T, Kokotas S, Kastrinakis N, Kotsinas A, Athanasiou A, Foukas P, Zoumpourlis V, Kletsas D, Ikononopoulos J, Asimacopoulos PJ, Kittas C, Field JK. *Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.* **Cancer Res.** 2001 Jan 15;61(2):538-49. **IF: 13.312**
305. Kanavaros P, Stefanaki K, Vlachonikolis J, Papalazarou D, Rontogianni D, Arvanitis D, Antonakopoulos G, **Gorgoulis V**, Bai M, Agnantis NJ. *Immunohistochemical expression of the p53, p21/Waf-1, Rb, p16 and Ki67 proteins in multiple myeloma.* **Anticancer Res.** 2000 Nov-Dec;20(6B):4619-25. **IF: 2.435**
306. Ikononopoulos JA, **Gorgoulis VG**, Kastrinakis NG, Galanos AA, Karameris A, Kittas C. *Experimental inoculation of laboratory animals with samples collected from sarcoidal patients and molecular diagnostic evaluation of the results.* **In Vivo.** 2000 Nov-Dec;14(6):761-5. **IF: 2.406**
307. Garinis GA, **Gorgoulis VG**, Mariatos G, Zacharatos P, Kotsinas A, Liloglou T, Foukas P, Kanavaros P, Kastrinakis NG, Vassilakopoulos T, Vogiatzi T, Field JK, Kittas C. *Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs).* **J Pathol.** 2001 Jan;193(1):55-65. **IF: 9.883**
308. Mariatos G, **Gorgoulis VG**, Zacharatos P, Kotsinas A, Vogiatzi T, Rassidakis G, Foukas P, Liloglou T, Tiniakos D, Angelou N, Manolis EN, Veslemes M, Field JK, Kittas C. *Expression of p16(INK4A) and alterations of the 9p21-23 chromosome region in non-small-cell lung carcinomas: relationship with tumor growth parameters and ploidy status.* **Int J Cancer.** 2000 Mar 20;89(2):133-41. **IF: 7.316**
309. Fotiadis C, Manolis EN, Troupis TG, **Gorgoulis VG**, Sechas MN. *Endoscopic resection of a large granular cell tumor of the esophagus.* **J Surg Oncol.** 2000 Dec;75(4):277-9. **IF: 2.885**
310. Kastrinakis NG, **Gorgoulis VG**, Foukas PG, Dimopoulos MA, Kittas C. *Molecular aspects of multiple myeloma.* **Ann Oncol.** 2000 Oct;11(10):1217-28. **IF: 51.769**
311. Mariatos G, **Gorgoulis VG**, Kotsinas A, Zacharatos P, Kokotas S, Yannoukakos D, Kittas C. *Absence of mutations in the functional domains of the human MDM2 oncogene in non-small cell lung carcinomas.* **Mutat Res.** 2000 Nov 30;456(1-2):59-63. **IF: 3.151**
312. **Gorgoulis VG**, Kotsinas A, Zacharatos P, Mariatos G, Liloglou T, Tsoli E, Kokotas S, Fassoulas C, Field JK, Kittas C. *Association of allelic imbalance at locus D13S171 (BRCA2) and p53 alterations with tumor kinetics and chromosomal instability (aneuploidy) in nonsmall cell lung carcinoma.* **Cancer.** 2000 Nov 1;89(9):1933-45. **IF: 6.921**


313. Athanasiou A, **Gorgoulis VG**, Zacharatos P, Mariatos G, Kotsinas A, Liloglou T, Karameris A, Foukas P, Manolis EN, Field JK, Kittas C. *c-mos immunoreactivity is an indicator of good prognosis in lung cancer*. **Histopathology**. 2000 Jul;37(1):45-54. **IF: 7.778**
314. **Gorgoulis VG**, Mariatos G, Manolis EN, Zacharatos P, Kotsinas A, Liloglou T, Vogiatzi T, Tsagkaraki A, Kokotas S, Tsoli E, Alchanatis M, Sfikakis PP, Asimacopoulos PJ, Field JK, Kittas C. *Allelic imbalance at the 5q14 locus is associated with decreased apoptotic rate in non-small cell lung carcinomas (NSCLCs). Possible synergistic effect with p53 gene alterations on apoptosis*. **Lung Cancer**. 2000 Jun;28(3):211-24. **IF: 6.081**
315. Kanavaros P, Stefanaki K, Vlachonikolis J, Eliopoulos G, Kakolyris S, Rontogianni D, **Gorgoulis V**, Georgoulis V. *Expression of p53, p21/waf1, bcl-2, bax, Rb and Ki67 proteins in Hodgkin's lymphomas*. **Histol Histopathol**. 2000 Apr;15(2):445-53. **IF: 2.130**
316. Ikonomopoulos JA, **Gorgoulis VG**, Kastrinakis NG, Zacharatos PV, Kokotas SN, Evangelou K, Kotsinas AG, Tsakris AG, Manolis EN, Kittas CN. *Sensitive differential detection of genetically related mycobacterial pathogens in archival material*. **Am J Clin Pathol**. 2000 Dec;114(6):940-50. **IF: 5.400**
317. **Gorgoulis VG**, Zacharatos P, Kotsinas A, Mariatos G, Liloglou T, Vogiatzi T, Foukas P, Rassidakis G, Garinis G, Ioannides T, Zoumpourlis V, Bramis J, Michail PO, Asimacopoulos PJ, Field JK, Kittas C. *Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs)*. **Mol Med**. 2000 Mar;6(3):208-37. **IF: 6.376**
318. Bouda M, **Gorgoulis VG**, Kastrinakis NG, Giannoudis A, Tsoli E, Danassi-Afentaki D, Foukas P, Kyroudi A, Laskaris G, Herrington CS, Kittas C. *"High risk" HPV types are frequently detected in potentially malignant and malignant oral lesions, but not in normal oral mucosa*. **Mod Pathol**. 2000 Jun;13(6):644-53. **IF: 8.209**
319. Garinis G, Patrinos GP, Menounos P, Spanakis N, **Gorgoulis VG**, Theodorou V, Ioannidis T, Karameris A, Valis D. *Evaluation of a minipool reverse transcription-PCR screening method for the detection of hepatitis C virus infection in hemodialysis patients*. **Clin Chem**. 2000 Apr;46(4):583-4. **IF: 12.167**
320. Fotiadis C, Sergiou C, Kirou J, Troupis TG, Tselentis J, Doussaitou P, **Gorgoulis VG**, Sechas MN. *Experimental echinococcus infection in the mouse model: pericyclic cellular immunity reaction and effects on the lymphoid organs of immunocompetent and thymectomized mice*. **In Vivo**. 1999 Nov-Dec;13(6):541-6. **IF: 2.406**
321. Mariatos G, **Gorgoulis VG**, Laskaris G, Kittas C. *Epithelioid hemangioma (angiolymphoid hyperplasia with eosinophilia) in the oral mucosa. A case report and review of the literature*. **Oral Oncol**. 1999 Jul;35(4):435-8. **IF: 5.972**
322. Fotiadis C, Zografos G, Aronis K, Troupis TG, **Gorgoulis VG**, Sechas MN, Skalkeas G. *The effect of various types of splenectomy on the development of B-16 melanoma in mice*. **Anticancer Res**. 1999 Sep-Oct;19(5B):4235-9. **IF: 2.435**
323. Guenova M, Rassidakis GZ, **Gorgoulis VG**, Angelopoulou MK, Siakantaris MR, Kanavaros P, Pangalis GA, Kittas C. *p16INK4A is regularly expressed in Hodgkin's disease: comparison with retinoblastoma, p53 and MDM2 protein status, and the presence of Epstein-Barr virus*. **Mod Pathol**. 1999 Nov;12(11):1062-71. **IF: 8.209**
324. Ikonomopoulos JA, **Gorgoulis VG**, Zacharatos PV, Manolis EN, Kanavaros P, Rassidakis A, Kittas C. *Multiplex polymerase chain reaction for the detection of mycobacterial DNA in cases of tuberculosis and sarcoidosis*. **Mod Pathol**. 1999 Sep;12(9):854-62. **IF: 8.209**

325. **Gorgoulis VG**, Tiniakos DG, Mariatos G, Manolis EN, Mitropoulos D, Kittas C. *Recent advances in early prostatic cancer*. **Anticancer Res.** 1999 May-Jun;19(3B):2327-48. **IF: 2.435**
326. Spanakis NE, **Gorgoulis V**, Mariatos G, Zacharatos P, Kotsinas A, Garinis G, Trigidou R, Karameris A, Tsimara-Papastamatiou H, Kouloukousa M, Manolis EN, Kittas C. *Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas*. **Anticancer Res.** 1999 May-Jun;19(3A):1893-9. **IF: 2.435**
327. Kanavaros P, Stefanaki K, Valassiadou K, Vlachonikolis J, Mavromanolakis M, Vlychou M, Kakolyris S, **Gorgoulis V**, Tzardi M, Georgoulis V. *Expression of p53, p21/waf, bcl-2, bax, Rb and Ki67 proteins in colorectal adenocarcinomas*. **Med Oncol.** 1999 Apr;16(1):23-30. **IF: 3.738**
328. Kanavaros P, Vlychou M, Stefanaki K, Rontogianni D, Gaulard P, Pantelidaki E, Zois M, Darivianaki K, Georgoulis V, Boulland ML, **Gorgoulis V**, Kittas C. *Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease*. **Anticancer Res.** 1999 Mar-Apr;19(2A):1209-16. **IF: 2.435**
329. Garinis G, Spanakis N, Theodorou V, **Gorgoulis V**, Manolis E, Karameris A, Valis D. *Comparison of the enzyme-linked immunosorbant assay III, recombinant immunoblot third generation assay, and polymerase chain reaction method in the detection of hepatitis C virus infection in haemodialysis patients*. **J Clin Lab Anal.** 1999;13(3):122-5. **IF: 3.124**
330. Zacharatos PV, **Gorgoulis VG**, Kotsinas A, Manolis EN, Liloglou T, Rassidakis AN, Kanavaros P, Field JD, Halazonetis T, Kittas C. *Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAF1/Cip1 and Bax genes in the lung cancer environment*. **Anticancer Res.** 1999 Jan-Feb;19(1A):579-87. **IF: 2.435**
331. **Gorgoulis VG**, Zacharatos P, Kotsinas A, Kyroudi A, Rassidakis AN, Ikonopoulou JA, Barbatis C, Herrington CS, Kittas C. *Human papilloma virus (HPV) is possibly involved in laryngeal but not in lung carcinogenesis*. **Hum Pathol.** 1999 Mar;30(3):274-83. **IF: 3.526**
332. **Gorgoulis VG**, Koutroumbi EN, Kotsinas A, Zacharatos P, Markopoulos C, Giannikos L, Kyriakou V, Voulgaris Z, Gogas I, Kittas C. *Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas*. **Mol Med.** 1998 Dec;4(12):807-22. **IF: 6.376**
333. Kotsinas A, **Gorgoulis V**, Zacharatos P, Zioris H, Triposkiadis F, Donta I, Kyriakidis M, Karayannacos P, Kittas C. *Antioxidant agent nimesulid and beta-blocker metoprolol do not exert protective effects against rat mitochondrial DNA alterations in adriamycin-induced cardiotoxicity*. **Biochem Biophys Res Commun.** 1999 Jan 27;254(3):651-6. **IF: 3.322**
334. **Gorgoulis VG**, Zacharatos P, Kotsinas A, Liloglou T, Kyroudi A, Veslemes M, Rassidakis A, Halazonetis TD, Field JK, Kittas C. *Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression*. **Am J Pathol.** 1998 Dec;153(6):1749-65. **IF: 5.770**
335. Ikonopoulou JA, **Gorgoulis VG**, Zacharatos PV, Kotsinas A, Tsoli E, Karameris A, Panagou P, Kittas C. *Multiplex PCR assay for the detection of mycobacterial DNA sequences directly from sputum*. **In Vivo.** 1998 Sep-Oct;12(5):547-52. **IF: 2.406**
336. **Gorgoulis VG**, Zacharatos PV, Manolis E, Ikonopoulou JA, Damalas A, Lamprinopoulos C, Rassidakis GZ, Zoumpourlis V, Kotsinas A, Rassidakis AN,

- Halazonetis TD, Kittas C. *Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene.* **Br J Cancer** 1998;77(3):374-84. **IF: 9.075**
337. **Gorgoulis VG**, Zoumpourlis V, Rassidakis GZ, Karameris A, Rassidakis AN, Spandidos DA, Kittas C. *A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma.* **J Pathol.** 1996 Oct;180(2):129-37. **IF: 9.883**
338. **Gorgoulis VG**, Rassidakis GZ, Karameris AM, Papastamatiou H, Trigidou R, Veslemes M, Rassidakis AN, Kittas C. *Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.* **Mod Pathol.** 1996 May;9(5):544-54. **IF: 8.209**
339. Giatromanolaki A, **Gorgoulis V**, Chetty R, Koukourakis MI, Whitehouse R, Kittas C, Veslemes M, Gatter KC, Iordanoglou I. *C-erbB-2 oncoprotein expression in operable non-small cell lung cancer.* **Anticancer Res.** 1996 Mar-Apr;16(2):987-93. **IF: 2.435**
340. **Gorgoulis V**, Sfrikakis PP, Karameris A, Papastamatiou H, Trigidou R, Veslemes M, Spandidos DA, Sfrikakis P, Jordanoglou J. *Molecular and immunohistochemical study of class I growth factor receptors in squamous cell lung carcinomas.* **Pathol Res Pract.** 1995 Oct;191(10):973-81. **IF: 3.309**
341. **Gorgoulis VG**, Barbatis C, Poulias I, Karameris AM. *Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients.* **Mod Pathol.** 1995 Sep;8(7):758-64. **IF: 8.209**
342. Karameris AM, Worthy E, **Gorgoulis VG**, Quezado M, Anastassiades OT. *p53 gene alterations in special types of breast carcinoma: a molecular and immunohistochemical study in archival material.* **J Pathol.** 1995 Aug;176(4):361-72. **IF: 9.883**
343. Giannoudis A, Ergazaki M, Segas J, Giotakis J, Adamopoulos G, **Gorgoulis V**, Spandidos DA. *Detection of Epstein-Barr virus and human papillomavirus in nasopharyngeal carcinoma by the polymerase chain reaction technique.* **Cancer Lett.** 1995 Mar 2;89(2):177-81. **IF: 9.756**
344. **Gorgoulis V**, Zoumpourlis V, Rassidakis G, Karameris A, Barbatis C, Spandidos DA, Kittas C. *Molecular analysis of p53 gene in laryngeal premalignant and malignant lesions. p53 protein immunohistochemical expression is positively related to proliferating cell nuclear antigen labelling index.* **Virchows Arch.** 1995;426(4):339-44. **IF: 4.535**
345. Spandidos D, Zoumpourlis V, **Gorgoulis V**, Gourtsoyiannis N. *P53 expression in human small-intestinal tumors.* **Oncol Rep.** 1994 Sep;1(5):885-7. **IF: 4.136**
346. **Gorgoulis V**, Tsatsanis C, Ozanne B, Spandidos D. *Detection of epidermal growth-factor receptor and C-erbB-2 gene amplification in transitional-cell bladder-carcinoma using the differential PCR technique.* **Int J Oncol.** 1994 Jun;4(6):1191-7. **IF: 5.884**
347. **Gorgoulis V**, Rassidakis G, Karameris A, Giatromanolaki A, Barbatis C, Kittas C. *Expression of p53 protein in laryngeal squamous cell carcinoma and dysplasia: possible correlation with human papillomavirus infection and clinicopathological findings.* **Virchows Arch.** 1994;425(5):481-9. **IF: 4.535**
348. **Gorgoulis V**, Giatromanolaki A, Iliopoulos A, Kanavaros P, Aninos D, Ioakeimidis D, Kontomerkos T, Karameris A. *EGF and EGF-r immunoexpression in Sjögren's syndrome secondary to rheumatoid arthritis. Correlation with EBV expression?* **Clin Exp Rheumatol.** 1993 Nov-Dec;11(6):623-7. **IF: 4.862**

349. Mikou P, Kanavaros P, Aninos D, Tzardi M, Karameris A, **Gorgoulis B**, Papadopoulos N, Lavergne A, Galian A. *Nucleolar organizer regions (NORs) staining and proliferating cell nuclear antigen (PCNA) immunostaining in mucosa-associated lymphoid tissue (MALT) gastric lymphomas.* **Pathol Res Pract.** 1993 Nov;189(9):1004-9. **IF: 3.309**
350. Karameris A, Kanavaros P, Aninos D, **Gorgoulis V**, Mikou G, Rokas T, Niotis M, Kalogeropoulos N. *Expression of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in gastric and colorectal carcinomas. An immunohistological study of 63 cases.* **Pathol Res Pract.** 1993 Mar;189(2):133-7. **IF: 3.309**
351. **Gorgoulis V**, Giatromanolaki A, Karameris A, Tsatsanis C, Aninos D, Ozanne B, Veslemes M, Jordanoglou J, Trigidou R, Papastamatiou H, et al. *Epidermal growth factor receptor expression in squamous cell lung carcinomas: an immunohistochemical and gene analysis in formalin-fixed, paraffin-embedded material.* **Virchows Arch A Pathol Anat Histopathol.** 1993;423(4):295-302. **IF: 4.535**
352. **Gorgoulis V**, Aninos D, Mikou P, Kanavaros P, Karameris A, Joardanoglou J, Rasidakis A, Veslemes M, Ozanne B, Spandidos DA. *Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas.* **Anticancer Res.** 1992 Jul-Aug;12(4):1183-7. **IF: 2.435**
353. Karameris A, **Gorgoulis V**, Iliopoulos A, Frangia C, Kontomerkos T, Ioakeimidis D, Kalogeropoulos N, Sfrikakis P, Kanavaros P. *Detection of the Epstein Barr viral genome by an in situ hybridization method in salivary gland biopsies from patients with secondary Sjögren's syndrome.* **Clin Exp Rheumatol.** 1992 Jul-Aug;10(4):327-32. **IF: 4.862**
354. **Gorgoulis V**, Aninos D, Priftis C, Evagelopoulou C, Karameris A, Kanavaros P, Spandidos DA. *Expression of epidermal growth factor, transforming growth factor-alpha and epidermal growth factor receptor in thyroid tumors.* **In Vivo.** 1992 May-Jun;6(3):291-6. **IF: 2.406**

Appendix I



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

National Institutes of Health
Bethesda, Maryland 20892

Curtis C. Harris, Chief

National Cancer Institute, NIH
Laboratory of Human Carcinogenesis
Building 37, Room 3068A
37 Convent Drive Bethesda, MD 20892-4258
Tel: 240-760-6420
Fax: 240-541-4496
Email: Curtis_Harris@nih.gov

June 12, 2018

Letter of Statement for Professor Vassilis G. Gorgoulis

I am writing this Letter of Statement to underline the substantial role of Professor Vassilis G. Gorgoulis in the fulfillment of the recently published paper in Nature Communications entitled “**Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246**” [Nat Commun. 2018 Feb 22;9(1):771. doi: 10.1038/s41467-018-03224-w]. Professor Vassilis G. Gorgoulis and his team played a vital role in the assembly of the manuscript, providing expert pathology contribution and significant experimental and conceptual support. Therefore, I consider him as co-senior in this publication.


Sincerely,

A handwritten signature in black ink, appearing to read "Curtis Harris", written in a cursive style.

Appendix II


Studies recognized as landmarks in the field of cancer biology

1) Lavin MF, *Nature Reviews Molecular Cell Biology* 2008.




Citing publications related to achievement 1 (see section: 4. MAJOR SCIENTIFIC ACHIEVEMENTS)

2) Malumbres M & Barbacid M, *Nature Reviews Cancer*, 2009;



Citing publications related to achievement 1 (see section: 4. MAJOR SCIENTIFIC ACHIEVEMENTS)

3) *Dobbelstsein M & Sorensen CS, Nature Reviews, Drug Discovery 2015.*



Citing publications related to achievement 1 (see section: 4. MAJOR SCIENTIFIC ACHIEVEMENTS)